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INTRODUCTION 
 
Le système vasculaire est le premier système à se former chez l'embryon de 
mammifère. Son développement commence par la différenciation in situ 
d'hémangioblastes, précurseurs des cellules endothéliales et hématopoïétiques, à 
partir du mésenchyme embryonnaire. Il s'ensuit une prolifération et une migration des 
cellules endothéliales pour former l'arbre vasculaire primitif au cours d'un processus 
appelé vasculogenèse (Risau and Flamme, 1995). Cet arbre vasculaire primitif est 
remodelé en un réseau comprenant des vaisseaux sanguins de différents calibres. 
Avec la croissance de l'embryon, de nouveau vaisseaux sanguins se forment à partir 
de la microcirculation pré-existante, lors d'un processus appelé angiogenèse 
(Flamme et al., 1997; Risau, 1997).  
 
Les capillaires sont les plus petits vaisseaux, ils permettent la diffusion de l'oxygène 
et de nutriments vers les tissus environnants. Le sang arrive aux capillaires par des 
artères, des vaisseaux de plus grand calibre, et repart par les veines. Ces trois types 
de vaisseaux sanguins diffèrent par la constitution de leur paroi vasculaire. En effet, 
suite au battement du cœur, un flux sanguin traverse les vaisseaux induisant les 
cellules endothéliales à émettre un signal vers les cellules mésenchymateuses 
environnantes. Ces dernières vont être induites à proliférer, migrer vers les cellules 
endothéliales puis se différencier en cellules péri-vasculaires appelées péricytes pour 
les capillaires et cellules musculaires lisses pour les artères et les veines. 
 
Il s'ensuit une phase de maturation pendant laquelle une interaction s'établit entre les 
cellules endothéliales et les cellules péri-vasculaires. Le contact entre ces deux types 
de cellules induit une stabilisation des cellules endothéliales en les rendant 
réfractaires au stimulus pro- ou anti-angiogénique (Benjamin et al., 1999; Benjamin 
et al., 1998). Les cellules musculaires lisses vont s'apposer concentriquement autour 
des tubes de cellules endothéliales afin de former une paroi vasculaire fonctionnelle.  
 
Plus tardivement par rapport à la formation des vaisseaux sanguins, les vaisseaux 
lymphatiques se développent en bourgeonnant, puis en se détachant des veines pré-
existantes pour former un réseau parallèle, selon un processus que l'on appelle 
 1
lymphangiogenèse. Les vaisseaux lymphatiques se forment aussi à partir de 
précurseurs des cellules endothéliales lymphatiques, les lymphangioblastes, qui se 
sont différenciés in situ dans le mésenchyme (Rodriguez-Niedenfuhr et al., 2001). 
 
 
Figure 1. Le développement du réseau sanguin et lymphatique (Wilting et al., 2003).  
 
Chez l'adulte, l'angiogenèse s'observe physiologiquement par exemple lors du cycle 
menstruel féminin, pendant la gestation au niveau de la glande mammaire et du 
placenta, au cours de l'inflammation, des processus de réparation tissulaire et lors de 
l'ischémie tissulaire. L'on peut également observer la formation de nouveau 
vaisseaux sanguins dans des conditions pathologiques tel que la rétinopathie 
diabétique, l'artériosclérose, l'arthrite rhumatoïde, la croissance tumorale et les 
malformations vasculaires (Carmeliet, 2003). La connaissance des mécanismes 
moléculaires qui règle l'angiogenèse est importante pour le développement de 
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nouveaux moyens thérapeutiques, avec comme but d'empêcher ou de stimuler la 
formation de nouveaux vaisseaux sanguins selon les circonstances. 
 
RÉGULATION DE L'ANGIOGENÈSE 
 
La recherche de molécules impliquées dans la régulation de l'angiogenèse a conduit 
à l'identification de plusieurs familles de protéines, en particulier des facteurs de 
croissance, des molécules d'adhésion et des enzymes protéolytiques (Carmeliet, 
2000). Parmi les cytokines impliquées dans la formation de nouveaux vaisseaux 
sanguins et dans l'assemblage correct de la paroi vasculaire, on trouve la famille des 
vascular endothelial growth factor (VEGF), des fibroblast growth factor (FGF), 
platelet-derived growth factor (PDGF), des angiopoïétines (Ang) et les transforming 
growth factor-β (TGF-β). Les malformations ou les dysfonctions vasculaires 
compromettent de nombreuses fonctions organiques résultant à des maladies 
congénitales et acquises. Des mutations dans les gènes codant pour le récepteur 
des Ang, Tie-2 ou TEK, ainsi que pour deux récepteurs auxiliaires des TGF-β, 
endoglin (ENG) et activin receptor-like kinase 1 (ACVRL1), ont été identifiés chez 
des familles atteintes de malformations vasculaires (Brouillard and Vikkula, 2003). 
Les mutations de Tie-2 sont impliquées dans la survenue de malformations 
veineuses et les mutations d'ENG et ACVLR-1 dans l'apparition de télangiectasies 
hémorragiques héréditaires. Ces deux maladies ont en commun un défaut dans 
l'assemblage de la paroi vasculaire.  
 
Le processus d'angiogenèse à partir d'un vaisseau pré-existant peut être divisé en 
plusieurs phases. Dans la partie de la paroi vasculaire destinée à émettre un 
nouveau capillaire, il y a tout d'abord une perte de contact entre les cellules 
endothéliales et les péricytes avec une augmentation de la perméabilité vasculaire 
par Ang-2 et VEGF-A. Suite à cette activation, les cellules endothéliales dégradent 
protéolytiquement leur lame basale, prolifèrent et migrent à travers la matrice extra-
cellulaire vers la source angiogénique en formant un capillaire dépourvu de cellules 
péri-vasculaires. Ultérieurement, il y a recrutement et différenciation des cellules péri-
vasculaires par TGF-β1, PDGF-BB et Ang-2 afin de former un vaisseau sanguin avec 
une paroi non perméable et fonctionnelle. Parmi les divers facteurs angiogéniques la 
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famille la plus étudiée est celle des VEGF qui a pour cible principale les cellules 
endothéliales (Ferrara et al., 2003). 
 
LA FAMILLE DES VEGF 
 
La famille des VEGF consiste en des dimères de glycoprotéines qui ont en commun 
un domaine d'homologie des VEGF. Celui-ci est composé de 8 cystéines impliquée 
dans les liaisons disulfures des dimères (McDonald and Hendrickson, 1993). La 
famille des VEGF comprend plusieurs membres de protéines sécrétées, jouant un 
rôle important dans la physiologie et la pathologie du système vasculaire, incluant la 
vasculogenèse, l'hématopïèse, l'angiogenèse et la lymphangiogenèse (Jussila and 
Alitalo, 2002). Cette famille se compose de VEGF-A, VEGF-B, VEGF-C, VEGF-D et 
PlGF. L'effet des VEGF se fait par l'intermédiaire de trois récepteurs tyrosine kinase 
nommé VEGFR-1/Flt-1, VEGFR-2/KDR/Flk-1 et VEGFR-3/Flt-4. Le profil de liaisons 
des VEGF à ces récepteurs n'est pas spécifique à un membre en particulier. En effet, 
VEGFR-1 lie VEGF-A, -B et PlGF-1,-2 , VEGFR-2 lie VEGF-A, -C et -D tandis que 
VEGFR-3 lie VEGF-C et -D.  
 
 
Figures 2. La famille des VEGF et ses récepteurs (Ferrara et al., 2003). 
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VEGF-A fut le premier facteur découvert ayant une activité mitotique spécifique sur 
les cellules endothéliales (Ferrara and Henzel, 1989). Il existe plusieurs isoformes de 
VEGF-A produites par épissage alternatif, la plus abondante et la plus étudiée étant 
celle contenant 165 acides aminés (Ferrara et al., 2003). L'importance de VEGF-A 
dans l'angiogenèse a été montré dans divers modèles expérimentaux in vivo. Chez 
la souris, l'inactivation du gène de VEGF-A conduit à une mort embryonnaire et ceci 
même à l'état hétérozygote (Carmeliet et al., 1996; Ferrara et al., 1996). Si l'on 
inactive VEGF-A spécifiquement à partir de la période néonatale, il en résulte, entre 
autres, un retard de la croissance létal (Gerber et al., 1999). Ceci démontre bien la 
nécessité de VEGF-A en ce qui concerne le développement physiologique de 
l'organisme. De même, son importance dans l'induction angiogénique lors de la 
croissance tumorale a été mise en évidence dans un modèle animal de 
transformation oncogénique des cellules bêta des îlots pancréatiques (Bergers et al., 
2000; Inoue et al., 2002). 
 
VEGF-B est un ligand spécifique pour VEGFR-1 (Olofsson et al., 1998). Son transcrit 
subit un épissage alternatif produisant deux isoformes de 167 et 186 acides aminés. 
Suite à leur sécrétion, VEGF-B167 reste associé avec la surface cellulaire par un 
domaine liant l'héparine, tandis que VEGF-B186 est librement diffusible (Olofsson et 
al., 1996). Basé sur la distribution tissulaire ainsi que sur le phénotype, suite à 
l'inactivation du gène codant pour VEGF-B, celui-ci participe au recrutement de 
cellules inflammatoires dans un modèle d'arthrite, au développement de la 
conduction cardiaque, mais n'est pas nécessaire à l'angiogenèse embryonnaire 
(Aase et al., 2001; Bellomo et al., 2000; Mould et al., 2003; Olofsson et al., 1996).  
 
PlGF est transcrit en 2 isoformes par épissage alternatif, PlGF-1 et PlGF-2 chez 
l'homme, seul PlGF-2 est exprimé chez la souris (DiPalma et al., 1996). PlGF-2 
contient 21 acides aminés supplémentaire dans sans sa partie C-terminale lui 
permettant de lié l'héparine (Hauser and Weich, 1993; Migdal et al., 1998). Chez la 
souris, l'inactivation du gène codant pour PlGF-2 affecte l'angiogenèse pathologique 
(Luttun et al., 2002a). PlGF-2 agit sur l'activation des cellules endothéliales, le 
recrutement des cellules musculaire lisse et le recrutement des cellules 
inflammatoires à partir de la moelle osseuse (Hattori et al., 2002; Heissig et al., 
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2002). PlGF est nécessaire à l'augmentation de la perméabilité induite par VEGF-A 
(Carmeliet et al., 2001). 
 
VEGF-C et VEGF-D sont deux membres de la famille des VEGF impliqués dans la 
lymphangiogenèse en plus d'un possible rôle dans l'angiogenèse (Jussila and Alitalo, 
2002). Ces deux cytokines sont sécrétés sous forme d'homodimère, puis sous 
l'action d'enzymes protéolytiques comme la plasmine et les furins PC5 et PC7 
(McColl et al., 2003; Siegfried et al., 2003), ils subissent extracellulairement un 
clivage de leur partie N- et C-terminales. Ces clivages successifs modulent la 
capacité de VEGF-C et VEGF-D à lier VEGFR-2 et VEGFR-3 et par la même 
modifient l'effet biologique de ces cytokines. La forme partiellement transformée de 
31 kDa, ayant subit le clivage de la partie C-terminale, lie et active VEGFR-3 tandis 
que la protéine mature de 21 kDa, qui a subit le clivage des parties N- et C-
terminales, lie et active VEGFR-2 en plus de VEGFR-3 (Joukov et al., 1997). 
L'inactivation de gène codant pour VEGF-C résulte en une altération du 
développement des vaisseaux lymphatiques sans affecté le développement 
vasculaire (Karkkainen et al., 2003). 
 
Les récepteurs à VEGF sont de type tyrosine kinase. Après le dimérisation suite à la 
stimulation par le ligand, il y a autophosphorylation des récepteurs. Les VEGFR sont 
exprimés à un faible niveau dans beaucoup de tissus adultes mais leur niveau 
d'expression dans les cellules endothéliales est augmenté pendant le développement 
ainsi que dans des pathologies où l'angiogenèse joue un rôle important. 
L'inactivation des gènes codant pour VEGFR-1, VEGFR-2 ou VEGFR-3 résultent 
chacune en une létalité embryonnaire chez la souris.  
 
L'inactivation du gène codant pour VEGFR-1 induit un surnombre de cellules 
endothéliales ayant comme conséquence une altération de la vasculogenèse (Fong 
et al., 1995; Fong et al., 1999). Par contre, l'inactivation de la partie tyrosine kinase 
de VEGFR-1 est compatible avec le développement normal chez la souris, alors 
qu'elle affecte l'angiogenèse tumorale (Hiratsuka et al., 2001; Hiratsuka et al., 1998). 
Pendant l'embryogenèse, VEGFR-1 servirait de récepteur "réservoir" pour VEGF-A 
réglant sa disponibilité pour VEGFR-2 ainsi que son activité transmise par cette 
liaison à VEGFR-2. Dans l'angiogenèse pathologique VEGFR-1 participe au 
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développement de lésions artéromateuses et dans l'arthrite (Luttun et al., 2002b). 
L'inhibition de VEGFR-1 affecte l'infiltration monocytaires diminuant ainsi la 
progression des plaques. Dans un modèle murin d'arthrite, l'inhibition de VEGFR-1 
diminue l'œdème, l'érythème et l'ankylose (Luttun et al., 2002b). Dans ces deux 
modèles, VEGFR-1 est nécessaire à la mobilisation de précurseurs de cellules 
endothéliales à partir de la moelle osseuse (Carmeliet et al., 2001; Lyden et al., 
2001). Il semble que VEGF-B et PlGF soit nécessaire pour la réponse biologique 
induite par la phosphorylation de VEGFR-1 (Autiero et al., 2003). 
 
L'inactivation du gène codant pour VEGFR-2 chez la souris résulte en un manque de 
développement d'hémangioblastes, ce qui affecte la vasculogenèse (Shalaby et al., 
1995). Des données in vitro et in vivo ont démontré l'importance de l'activation par 
VEGF-A, de VEGFR-2 dans les cellules endothéliales en ce qui concerne l'induction 
spécifique de gènes, la migration, la prolifération, la perméabilité vasculaire, ainsi 
que dans l'angiogenèse (Ferrara et al., 2003). La forme mature de VEGF-C et VEGF-
D lie et active également VEGFR-2 en plus de VEGFR-3 (Jussila and Alitalo, 2002). 
Actuellement, il n'est pas certain que l'activation de VEGFR-2 par ces différents 
ligands induise les mêmes voies de signalisation et donc une réponse physiologique 
identique. Une mutation somatique dans le gène codant pour VEGFR-2 a été 
démontrée au niveau des cellules endothéliales d'hémangiome, une pathologie 
vasculaire ayant comme caractéristique une prolifération de capillaires sanguins 
(Walter et al., 2002). 
 
VEGFR-3 est traduit en un précurseur qui subit un clivage protéolytique dans sa 
partie extra-cellulaire, celle-ci restant liée à sa partie trans-membranaire par des 
ponts disulfures (Jussila and Alitalo, 2002). Au stade embryonnaire, VEGFR-3 est 
exprimé au niveau de tout l'arbre vasculaire puis se restreint aux vaisseaux 
lymphatiques et à certains capillaires fenestrés (Kaipainen et al., 1995; Partanen et 
al., 2000). L'inactivation du gène codant pour VEGFR-3 résulte en un défaut dans le 
remodelage de l'arbre vasculaire avant l'apparition des vaisseaux lymphatiques 
(Dumont et al., 1998). La différenciation des cellules endothéliales, ainsi que la 
vasculogenèse, ne sont pas affectées par l'absence de VEGFR-3, par contre le 
développement de l'hématopoïèse au niveau de la membrane vitelline est diminuée, 
suggérant un rôle pour VEGFR-3 dans l'hématopoïèse (Hamada et al., 2000). Dans 
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l'angiogenèse tumorale, VEGFR-3 est ré-exprimé au niveau des cellules 
endothéliales des vaisseaux sanguins (Clarijs et al., 2002; Valtola et al., 1999). Le 
blocage de VEGFR-3, lors du processus tumoral, résulte en une altération de 
l'angiogenèse et entraîne une diminution de la croissance tumorale (Kubo et al., 
2000). VEGFR-3 est impliqué dans le lymphoedème héréditaire de type I (Irrthum et 
al., 2000; Karkkainen et al., 2000). Cette maladie se transmet de manière 
autosomale dominante et les mutations décrites se trouvent dans la partie kinase de 
VEGFR-3. Ces mutations affectent la capacité d'autophosphorylation du récepteur 
empêchant ainsi l'activation de la voie de signalisation (Irrthum et al., 2000; 
Karkkainen et al., 2000). De plus, dans les hémangiomes, une mutation somatique 
dans la partie kinase de VEGFR-3 a été démontrée dans les cellules endothéliales 
de la lésion, mais pas dans celles du tissu sain environnant (Walter et al., 2002).  
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OBJECTIF DE LA THÈSE 
 
 
L'importance de la famille des facteurs de croissance de l'endothélium vasculaire 
(vascular endothelial growth factor, VEGF) dans la physiologie et la pathologie du 
système vasculaire nous a amené à étudier les différents récepteurs de cette famille 
(VEGFR) exprimés par les cellules endothéliales.  
 
Dans une première partie, j'ai étudié le rôle de VEGFR-1, -2 et -3 dans l'angiogenèse 
in vivo et in vitro, ainsi que dans la régulation des gènes induits par la famille des 
VEGF et FGF-2. 
 
Dans une deuxième partie, j'ai étudié l'interaction entre cellules endothéliales et 
cellules mésenchymateuses, précurseurs des cellules péri-vasculaires, lors du 
processus d'angiogenèse in vitro induite par VEGF-A et FGF-2. 
 
Dans la dernière partie, j'ai étudié une famille atteinte d'une malformation vasculaire 
héréditaire en caractérisant le type de vaisseaux présents dans la lésion. De plus, j'ai 
étudié l'association entre une prédisposition pour cette pathologie et la transmission 
de gènes impliqués dans le développement vasculaire.  
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ABSTRACT
Exponential tumor growth is angiogenesis-dependent. Vascular
endothelial growth factor (VEGF) and basic fibroblast growth
factor (bFGF) are potent angiogenic inducers that act synergis-
tically in vivo and in vitro. We assessed the effect of specific
inhibitors of VEGF receptor (VEGFR)-2 tyrosine kinase activity
in in vivo and in vitro models of VEGF- and bFGF-induced
angiogenesis. In an implant mouse model of angiogenesis,
VEGFR-2 inhibitors completely blocked angiogenesis induced
by VEGF, and, surprisingly, also inhibited the effect of bFGF to
various extents. In vitro, VEGF- and bFGF-induced bovine mi-
crovascular and aortic endothelial (BME and BAE) cell collagen
gel invasion could be blocked by the VEGFR-2 inhibitors by 100
and 90%, respectively. Similar results were obtained with
VEGFR-1-IgG and VEGFR-3-IgG fusion proteins and with
VEGFR-2 blocking antibodies. Both BME and BAE cells pro-
duce VEGF and VEGF-C, which is not modulated by bFGF.
Thus, the unexpected inhibition of bFGF-induced angiogenesis
by VEGFR-2 antagonists reveals a requirement for endogenous
VEGF and VEGF-C in this process. These findings broaden the
spectrum of mediators of angiogenesis that can be inhibited by
VEGFR-2 antagonists and highlight the importance of these
compounds as agents for inhibiting tumor growth sustained by
both VEGF and bFGF.
Angiogenesis, the process by which new capillary blood
vessels originate from pre-existing vessels, is an absolute
requirement for the establishment of a vascular supply in
both normal and neoplastic tissues. During angiogenesis,
previously quiescent endothelial cells are stimulated to de-
grade their basement membrane and to invade the surround-
ing stroma, initially as solid endothelial cell cords. Later,
these cords develop a lumen and deposit a new basement
membrane, thus resulting in functional new capillaries. Sev-
eral molecules affect one or more endothelial cell functions
involved in these processes. Many are polypeptide growth
factors, among which acidic and basic fibroblast growth fac-
tors (bFGF) and vascular endothelial growth factor/vascular
permeability factor (VEGF/VPF; referred as VEGF in this
paper) are the best characterized. FGFs and VEGF are mi-
togenic for endothelial cells and stimulate endothelial cell
migration and pericellular proteolysis (for review, see Ger-
wins et al., 2000).
VEGF is an endothelial cell-specific mitogen that acts
through two tyrosine kinase receptors, VEGFR-1/Flt and
VEGFR-2/Flk-1/KDR, whose expression is restricted to endo-
thelial cells, monocytes, and hematopoietic precursors. Dis-
ruption of either the VEGFR-1 or the VEGFR-2 gene results
in lethal embryonic vascular and/or hematopoietic abnormal-
ities. Similar defects have been described in mice lacking a
single copy of the VEGF gene, which indicates a crucial
dose-dependent requirement for VEGF during early develop-
ment (for review, see Ferrara, 2001). VEGF-C, a protein with
structural homology to VEGF, was the first VEGFR-3/Flt-4
ligand to be described (for review, see Veikkola et al., 2000).
VEGFR-3 is expressed widely in embryonic endothelium, but
in postnatal life becomes restricted to lymphatic endothelial
cells and some venules (Kaipainen et al., 1995). Based on its
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expression profile and binding to VEGFR-3, VEGF-C has
been implicated in the development of the lymphatic system,
and tissue-specific overexpression of VEGF-C in the mouse
results in a specific lymphangiogenic effect (Jeltsch et al.,
1997; Mandriota et al., 2001). However, the role of VEGF-C/
VEGFR-3 is not restricted to lymphangiogenesis. First, tar-
geted inactivation of the VEGFR-3 gene resulted in embry-
onic lethal vascular defects, before the emergence of
lymphatic vessels (Dumont et al., 1998). Second, VEGFR-3 is
re-expressed in blood vessels of some tumors (Valtola et al.,
1999; Kubo et al., 2000). Third, VEGF-C can induce angio-
genesis under certain circumstances (Cao et al., 1998; Wit-
zenbichler et al., 1998). Interestingly, both VEGF and
VEGF-C have been reported to synergize with bFGF in the
induction of angiogenesis in vitro (Pepper et al., 1992a, 1998).
The observation that VEGFR expression correlates well
with tumor angiogenesis points to VEGFR tyrosine kinase
activities as potential targets for anti-angiogenic tumor ther-
apies. Because VEGFR-2 is the main signal transducing re-
ceptor for VEGF, much effort has gone into the development
of VEGFR-2 tyrosine kinase inhibitors. Low molecular
weight compounds of different chemical classes (Fong et al.,
1999; Wood et al., 2000) have been developed that are potent
inhibitors of VEGFR tyrosine kinases. A series of 1-anilino-
phthalazines have been synthesized that not only inhibit
VEGFR-2 but also VEGFR-1 and VEGFR-3 and that do not
affect FGFR tyrosine kinase activity in the same dose range
(Bold et al., 2000a). These compounds completely block
VEGF activity in in vivo and in vitro models of angiogenesis
(Bold et al., 2000a; Wood et al., 2000). They also inhibit
tumor angiogenesis, tumor growth, and the formation of me-
tastasis in rodent tumor models (Wood et al., 2000).
In the present studies, we assessed the effects of several
1-anilino-phthalazines on VEGF- and bFGF-induced angio-
genesis in vivo and in vitro. Surprisingly, we observed inhi-
bition of angiogenesis induced by either cytokine, despite the
fact that 1-anilino-phthalazines specifically block the activity
of VEGFR-2 without effecting FGFR-1, -3, or -4. This
prompted us to assess whether bFGF-induced in vitro angio-
genesis may be dependent on endogenous VEGF and/or
VEGF-C. Using a variety of intra- and extracellular antago-
nists, we were able to demonstrate that bFGF-induced inva-
sion is indeed partially dependent on endogenous VEGF and
VEGF-C.
Materials and Methods
Reagents. The VEGFR-2 inhibitors PTK787/ZK222584, AAC789/
ZK202650, and AAD777/ZK202664 come from a series of anilino-
phthalazines discovered and synthesized by Novartis Pharma AG
(Basel, Switzerland) as part of a joint research collaboration with
Schering AG (Berlin, Germany). The discovery, structure, and profile
of these compounds is described in detail elsewhere (Bold et al.,
2000a, 2000b; Wood et al., 2000; Manley et al., 2001). Recombinant
human bFGF (155 amino acid form) was provided by Dr P. Sarmien-
tos (Farmitalia Carlo Erba, Milan, Italy). Recombinant human
VEGF (165-amino acid homodimeric isoform) was purchased from
Peprotech Inc. (Rocky Hill, NJ). Recombinant human VEGF-C
(NC) was provided by Dr. K. Alitalo (Molecular/Cancer Biology
Laboratory, Helsinki, Finland). VEGFR-1-IgG (Flt-IgG) and CD4-
IgG were provided by Dr. N. Ferrara (Genentech Inc., South San
Francisco, CA). VEGFR-3-IgG (Flt-4-IgG) was provided by Dr. W. I.
Wood (Genentech). Anti-human VEGFR-2 antibodies (p1C11 and
6.64) and an isotype control for p1C11 (C225) have been described
previously (Witte et al., 1998; Zhu et al., 1998).
Cell Culture. Human VEGFR-2/KDR-transfected CHO cells were
obtained from the Institute of Molecular Medicine, Tumor Biology
Center (Freiburg, Germany). Human umbilical vein endothelial
(HUVE) cells (Promo Cell Nr. C-12250, BioConcept AG, Switzerland)
were cultivated in endothelial cell growth medium (Promo Cell Nr.
C-22110). Bovine adrenal cortex-derived microvascular endothelial
(BME) cells (Furie et al., 1984) were grown in minimal essential
medium, -modification (MEM; Invitrogen, Carlsbad, CA), supple-
mented with 5% heat-inactivated donor calf serum (DCS) (Flow
Laboratories, Baar, Switzerland), penicillin (110 U/ml), and strepto-
mycin (110 g/ml). Bovine aortic endothelial (BAE) cells, isolated
from scrapings of adult bovine thoracic aortas and cloned by limiting
dilution as previously described (Pepper et al., 1992b), were cultured
in low glucose Dulbecco’s modified minimal essential medium
(DMEM) (Invitrogen) supplemented with 10% DCS and antibiotics.
VEGF-Receptor Tyrosine Kinase Assays. In vitro kinase as-
says were performed in 96-well plates as a filter binding assay using
recombinant GST-fused kinase domains expressed in baculovirus
and purified over glutathione-Sepharose. [-33P]ATP was used as the
phosphate donor and poly-(Glu:Tyr 4:1) peptide (Sigma, Buchs, Swit-
zerland) was used as the acceptor. Recombinant GST-fusion proteins
were diluted in 20 mM Tris-HCl, pH 7.5, containing 1 to 3 mM
MnCl2, 3 to 10 mM Mg Cl2, 0.25 mg/ml PEG 20000, and 1 mM DTT,
according to their specific activity. Each GST-fused kinase was in-
cubated under optimized buffer conditions (20 mM Tris-HCl buffer,
pH 7.5, 1–3 mM MnCl2, 3–10 mM MgCl2, 3–8 g/ml poly-(Glu:Tyr
4:1), 0.25 mg/ml PEG 20000, 8 M ATP, 10 M sodium vanadate, 1
mM DTT, and 0.2 Ci [-33P]ATP) in a total volume of 30 l in the
presence or absence of the test substance for 10 min at room tem-
perature. The reaction was stopped by adding 10 l of 250 mM
EDTA. Using a 96-well filter system, half of the volume (20 l) was
transferred onto an Immobilon-PVDF membrane (Millipore, Bed-
ford, MA). The membrane was washed extensively in 0.5% H3PO4
and then soaked in ethanol. After drying, Microscint cocktail (Pack-
ard, Meriden, CT) was added, and scintillation counting was per-
formed. IC50 values in these and all assays described below were
calculated by linear regression analysis of the percentage inhibition.
Kinase Selectivity Assays. To determine the enzyme selectivity
profile of the compounds, their effects on the kinase activity of
human VEGFR-1, human and mouse VEGFR-2, human VEGFR-3,
human PDGFR-, human PDGFR-, human FGFR-1, human
FGFR-3, human FGFR-4, and human Tie-2 were measured using the
same substrate and procedure as described above for VEGF receptor
kinases.
In Vitro Cell Proliferation Assays. HUVE cell proliferation
was determined by measuring the incorporation of the pyrimidine
analog bromodeoxyuracil (BrdU) into DNA using the Biotrak Cell
Proliferation Elisa System V.2 (Amersham Pharmacia Biotech AB,
Uppsala, Sweden). Cells were seeded into 1.5% gelatin-coated 96-
well plates (5  103 cells per well) and incubated in endothelial cell
growth medium containing 5% FCS for 24 h. The medium was
replaced with essential basic medium (1.5% FCS), and the cells were
incubated for another 24 h. Essential basic medium was then re-
placed with fresh medium containing either 50 ng/ml VEGF or 0.5
ng/ml bFGF. Inhibitors were added just before addition of growth
factors. The cells were incubated for a further 24 h before adding the
BrdU labeling solution. Twenty four hours later, the labeling solu-
tion was removed, the cells were fixed, and the incorporated BrdU
was visualized with a peroxidase-labeled anti-BrdU antibody and
TMB substrate, as described by the manufacturer.
BME cells were seeded into 23-mm wells (Costar, Cambridge, MA)
at 10,000 cells per well in MEM  5% DCS. Two hours later,
inhibitors and cytokines were added at the indicated concentrations.
Medium and cytokines were renewed after 2 days, and cells were
trypsinized and counted after a further 2 days using a FACScan
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analyzer (Becton-Dickinson, San Jose, CA). Results are shown as the
mean of duplicate wells from two independent experiments.
VEGFR-2 Phosphorylation Assays. Human VEGFR-2-trans-
fected CHO cells were seeded into 6-well plates and grown to
about 80% confluency. Inhibitor was added in serial dilutions and
the cells incubated for 2 h at 37°C in medium without FCS. VEGF
(20 ng/ml) was then added. After a 5-min incubation at 37°C, the
cells were washed twice with ice-cold phosphate-buffered saline
and lysed (50 mM Tris-HCl, pH 7.4, 150 mM sodium chloride, 5
mM EDTA, 1 mM EGTA, 1% NP-40, 2 mM sodium ortho-vanadate,
1 mM phenylmethylsulfonyl fluoride, 50 mg/ml aprotinin, and 80
mg/ml leupeptin). Nuclei were removed by centrifugation for 10
min at 4°C. Protein concentrations of the lysates were determined
using BSA as a standard. Microtiter plates were coated with a
monoclonal antibody to human VEGFR-2/KDR (Mab 1495.12.14,
Novartis), which served as a capture antibody. Cell lysates (20 g
of protein per well) were added in triplicate together with PY-
20(AP), an alkaline phosphatase-labeled anti-phosphotyrosine an-
tibody (Transduction Laboratories, Lexington, KY). After an over-
night incubation at 4°C, the bound PY-20(AP) was detected by
chemiluminescence with a luminescent alkaline phosphatase sub-
strate (TROPIX, Bedford, MA).
In Vivo Growth Factor-Induced Angiogenesis Model. Porous
Teflon chambers (volume, 0.5 ml) filled with 0.8% w/v agar-contain-
ing heparin (20 U/ml) with or without VEGF (2 g/ml) or bFGF (0.3
g/ml) were implanted subcutaneously on the dorsal flank of female
mice (MAG; Novartis). The mice were treated with compounds (p.o.
once daily) or vehicle (5% dimethyl sulfoxide, 1% Tween 80 in water)
starting 1 day before implantation of the chamber and continuing for
5 days thereafter. At the end of the treatment period, the mice were
killed, and the chambers were removed. The vascularized tissue
growing around the chamber was removed carefully and weighed,
and the blood content was assessed by measuring hemoglobin levels
(Drabkins method; Sigma). The percentage inhibition of the angio-
genic response (increase in tissue weight or total blood) was calcu-
lated as follows for individual animals receiving the drug treatment
and chambers containing growth factor: (A  B)/(C  D)  100,
where A is the weight (or blood volume) of the tissue from a drug-
treated mouse with a chamber containing growth factor; B is the
mean weight (or blood volume) of the tissue from the group of
drug-treated mice with chambers not containing growth factor; C is
the mean weight (or blood volume) of the tissue from the group of
vehicle-treated mice with chambers containing growth factor; and D
is the mean background weight (or blood volume) of the tissue from
the group of vehicle-treated mice with chambers not containing
growth factor. EC50 values were estimated from the dose response
curves (% inhibition versus dose) plotted using a sigmoidal curve
fitting program (Origin 6.0; Microcal Software, Inc., Northampton,
NA). Each experiment was performed with six animals per dose
group and each dose was tested in at least two independent experi-
ments.
In Vitro Angiogenesis Assay. The in vitro angiogenesis assay
was performed as described (Montesano and Orci, 1985). BME cells
were seeded onto 500-l three-dimensional rat type I collagen gels in
16-mm tissue culture wells (Nunc), at 0.5 to 1.0  105 cells/well in
500 l of MEM  5% DCS. Upon reaching confluence (3 days), DCS
was reduced to 2%, and the cells were treated with bFGF; VEGF;
VEGF-C; neutralizing polyclonal anti-VEGF antibodies (R&D Sys-
tems, Minneapolis, MN); anti-trinitrophenol antibody (Pharmingen,
San Diego, CA); preimmune rabbit -globulins; soluble VEGFR-1-
IgG, VEGFR-3-IgG, or CD4-IgG; anti-VEGFR-2 antibodies; or
VEGF-R2 kinase inhibitors. Medium, cytokines, and antagonists
were renewed after 2 days, and after a further 2 days cultures were
photographed under phase contrast microscopy using a Nikon Dia-
phot TMD inverted photomicroscope (Nikon, Tokyo, Japan). Quan-
titation was performed as described (Pepper et al., 1992a). Results
are shown as the mean additive sprout length S.E.M. (in microme-
ters) for at least three experiments per condition. Mean values were
compared using the Student’s unpaired t test, and a significant p
value was taken as0.05. ED50 values were estimated from the dose
response curves plotted using a sigmoidal curve fitting program
(Origin 6.0).
RNA Purification and RNase Protection Assay. Total cellular
RNA was purified using Trizol reagent (Invitrogen). RNase protec-
tion assays were as described (Pepper et al., 1993a). [-32P]dUTP
cRNA probes were generated from partial bovine VEGF164 (this
paper), bovine VEGF-B, bovine VEGF-C, and bovine VEGF-D (M. S.
Pepper and S. J. Mandriota, manuscript in preparation) and bovine
acidic ribosomal phosphoprotein P0 cDNAs, the latter of which was
used as an internal control (Pepper and Mandriota, 1998). Autora-
diograms were scanned with a Laser ScanJet IIex Instrument
(Hewlett Packard, Palo Alto, CA) and bands were quantitated using
ImageQuant 3.3 (Molecular Dynamics, Sunnyvale, CA).
Reverse Transcription-Polymerase Chain Reaction (RT-
PCR). Two micrograms of total cellular RNA were combined with
random exanucleotides (Boehringer Mannheim, Mannheim, Ger-
many) and Moloney Murine Leukemia Virus reverse transcriptase
(Promega, Madison, WI) according to the manufacturer’s instruc-
tions. VEGF cDNAs were amplified from 1/20 of the volume of the RT
product using PrimeZyme DNA polymerase (Biometra, Go¨ttingen,
Germany) and a Biometra TRIO-Thermoblock instrument. The
primer sequences used were: for VEGF, forward: 5-CCGGAATTC-
CAGGAGTACCCAGATGAG; reverse: 5-CGCGGATCCGGCTCAC-
CGCCTCGGCTTGTC, located in the NH2-terminal region or in the
translational-end region, respectively, of the bovine VEGF cDNA,
the former upstream and the latter downstream of the alternative
splicing site (Leung et al., 1989). In a parallel PCR reaction, 1/20 of
the volume of the same RT products was amplified by a pair of
primers (forward: 5-CCGGAATTCATGCGTTACGTTGCCTCCTAC;
reverse: 5-CGCGGATCCGGCCAGCTTGCCGATACCCTG) located
in the coding region of the bovine acidic ribosomal protein P2 (Gen-
Bank accession number U17836). Cycles employed for PCR were as
follows: for VEGF: 95°C, 3 min (one time); 95°C, 1 min; 62°C, 1 min;
72°C, 1 min (27 times); 72°C, 10 min (one time); for P2: 95°C, 3 min
(one time); 95°C, 45 s; 64°C, 45 s; 72°C, 45 s (27 times); 72°C, 10 min
(one time). PCR products were electrophoresed in 6% (VEGF) or 8%
(P2) polyacrylamide gels and stained with ethidium bromide. For all
the semiquantitative RT-PCR reactions, preliminary experiments
were performed to determine the number of PCR cycles at which
saturation occurred, and the experiments mentioned were performed
with a number of cycles that precedes saturation. A 400-bp RT-
PCR product from bovine brain, amplified with the VEGF primer
pair described above, and corresponding in size to the expected Mr of
the 164-amino acid VEGF isoform (411 bp), was purified, digested
with EcoRI and BamHI (which are restriction sites included in the 5
ends of the primers), and subcloned into the corresponding sites of
pBluescriptKS() (Stratagene, La Jolla, CA). The insert was se-
quenced partially on both strands by the chain termination method
(Sanger et al., 1977). Analysis of a total of 323 bases revealed 99%
identity with the bovine VEGF164 cDNA (Leung et al., 1989).
Immunoprecipitation and Western Blotting. Immunoprecipi-
tation and detection of VEGFR-2 phosphorylation were performed as
previously described (Pepper and Mandriota, 1998). BME and BAE
cell VEGFR-2 was immunoprecipitated from cell lysates with a poly-
clonal antibody (sc-504; Santa Cruz Biochemicals, Santa Cruz, CA)
recognizing amino acids 1158 to 1345 in the mouse VEGFR-2 car-
boxy terminus. Immunoprecipitates were boiled for 3 min in the
presence of 100 mM DTT, run in a 5% SDS polyacrylamide gel, and
transferred to a PVDF membrane (Bio-Rad, Hercules, CA). Western
blotting analysis was performed with an anti-phosphotyrosine anti-
body (catalog number 05-321; Upstate Biotechnology, Lake Placid,
NY) and a polyclonal anti-VEGFR-2 antibody (sc-315; Santa Cruz
Biochemicals) recognizing the mouse carboxyl-terminal amino acids
1348 to 1367. For detection of VEGF and VEGF-C, confluent BME
and BAE cell monolayers in 100-mm tissue culture dishes were
incubated with bFGF (10 ng/ml) or cytokine-free medium for 8 and
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15 h. The cells were lysed in 50 mM Tris-HCl, pH 8.0, 0.5% SDS, 5
mM EDTA, 0.5% NP40, 1 mM phenylmethylsulfonyl fluoride, 200
Kallikrein Inhibitory Units aprotinin, and 1 g/ml pepstatin A. Cell
extracts (100 g) were electrophoresed in 12% SDS polyacrylamide
gels under nonreducing conditions and then transferred to a PVDF
membrane for 1 h at 100 V. The membrane was incubated overnight
at 4°C in 1% skim milk and 1% BSA in 10 mM Tris-HCl, pH 7.4, 0.15
M NaCl, and 0.1% Tween 20. VEGF or VEGF-C were detected by
incubating the membrane with a rabbit polyclonal anti-human
VEGF (1 g/ml; sc-507; Santa Cruz) or anti-human VEGF-C (1
g/ml; sc-9047; Santa Cruz) antibody for 1 h at room temperature.
After incubation with horseradish peroxidase-conjugated goat anti-
mouse IgG (diluted 1:10,000; sc-2004; Santa Cruz) for 1 h at room
temperature, immune complexes were detected with the enhanced
chemiluminescence ECL detection system (Amersham Pharmacia
Biotech). Membranes were exposed to audiographic films (Kodak,
Rochester, NY). Recombinant human VEGF or normal rabbit serum
were used as a control.
Zymography and Reverse Zymography. BME cells were
grown to confluence in 35-mm dishes in MEM  5% DCS. At
confluence, medium was removed and the cells were washed twice
with phosphate-buffered saline and then incubated with serum-free
medium containing 200 Kallikrein Inhibitory Units/ml Trasylol
(Bayer-Pharma AG, Zurich, Switzerland), cytokines and inhibitors
for 15 h. Supernatants and cells lysates were harvested and analyzed
by zymography and reverse zymography as previously described
(Pepper et al., 1990).
Migration Assay. Migration assays was performed in a 48-well
micro-chemotaxis chamber (AP48; NeuroProbe, Gaithersburg, MD).
Eight-micrometer polyvinylpyrrolidine-free polycarbonate filters
(NeuroProbe) were coated with collagen type I (100 g/ml) in 0.2%
acetic acid for 30 min at room temperature and air dried. The filter
was placed over the bottom chamber containing VEGF (100 ng/ml) or
bFGF (10 ng/ml) in DMEM  0.1% BSA-serum-free medium. BAE
cells were suspended in the same medium at 50,000 cells in 50 l and
were added to the upper chamber. For assessment of the inhibitory
activity of VEGFR-2 kinase inhibitors, BAE cells were preincubated
in DMEM before addition to the upper chamber. The chamber was
incubated for 24 h at 37°C. Nonmigrated cells on the upper surface of
the filter were removed by scraping, and migrated cells on the lower
surface were fixed for 1 min in ethanol and stained for 1 min in 4%
Toludine blue. Filters were scanned, and spots were quantitated
using Scion Image software. Results are shown as the number of
migrating cells  S.E.M. (as a percentage of controls) for at least
three wells per condition.
Results
Characterization of the VEGF Receptor Tyrosine Ki-
nase Inhibitors. All compounds are potent inhibitors of the
human VEGFR-2 tyrosine kinase with similar or weaker
activity against its mouse counterpart (Table 1). These com-
pounds are also moderately active against VEGFR-1 and
VEGFR-3, but have little or no activity against PDGFR-
tyrosine kinases, and are all inactive against FGFR-1,
FGFR-3, FGFR-4, PDGFR-, and Tie-2 tyrosine kinases at
concentrations of up to 10 M (Table 1).
Because a kinase inhibitor must enter cells to inhibit the
kinase domain of the receptor, the effects of the inhibitors
was assessed on HUVE cell proliferation by measuring the
incorporation of the pyrimidine analog BrdU. All compounds
were found to be potent inhibitors of VEGF-induced HUVE
cell proliferation with an IC50 of 1.6 nM for AAC789, 5.8 nM
for PTK787, and 19.6 nM for AAD777. Furthermore, all
compounds were inactive against bFGF-induced proliferation
in the same concentration range; inhibition of bFGF-induced
HUVE cell proliferation was only observed at concentrations
100- to 1000-fold higher than those required to inhibit VEGF-
induced proliferation (data not shown).
All compounds inhibited VEGF-induced VEGFR-2 auto-
phosphorylation in a double antibody chemiluminescence
assay using CHO cells transfected with human VEGFR-2;
this was observed at the same concentrations at which
VEGF-induced HUVE cell proliferation was inhibited (Ta-
ble 1). To demonstrate the effect of PTK787 on VEGF-
induced receptor phosphorylation in endothelial cells ex-
pressing VEGFR-2 (Pepper and Mandriota, 1998),
confluent BAE cell monolayers were incubated with 10 M
PTK787 in the absence or presence of VEGF or bFGF. The
phosphorylation of VEGFR-2 was then examined by West-
ern blotting of VEGFR-2 immunoprecipitates. VEGF in-
duced phosphorylation of VEGFR-2 in BAE cells, and this
could be inhibited completely by 10 M PTK787 (Fig. 1).
No phosphorylation of VEGFR-2 by bFGF was observed at
longer incubation times (up to 8 h) and identical results
were obtained with BME cells (data not shown). To confirm
the specificity of the 200-kDa band, the Western blot was
reprobed with a second anti-VEGFR-2 antibody raised
TABLE 1
Inhibitory activity of receptor tyrosine kinase inhibitors
The enzymatic kinase assays were performed using recombinant GST-fused human
kinase domains of the receptor, excepted for VEGFR-2 were both mouse
(mVEGFR-2) and human (VEGFR-2) kinase domains were examined. VEGF-induced
cellular receptor phosphorylation was performed on CHO cells transfected with
human VEGFR-2. Each value represents the mean calculated from at least three
independent experiments.
PTK
787
AAC
789
AAD
777
Enzymatic IC50 (M)
VEGFR-1 0.107 0.38 3.0
mVEGFR-2 0.16 0.23 2.2
VEGFR-2 0.042 0.02 0.65
VEGFR-3 0.34 0.18 1.4
FGFR-1 	10 	10 	10
FGFR-3 	10 	10 	10
FGFR-4 	10 	10 	10
PDGFR- 	10 	10 	10
PDGFR- 2.3 1.4 	10
Tie-2 	10 	10 	10
Cellular IC50 (M)
CHO-hVEGFR-2 0.0113 0.0115 0.0266
Fig. 1. Inhibition of VEGFR-2 tyrosine phosphorylation by VEGFR-2
tyrosine kinase inhibitors. BAE cells were incubated with 10 M PTK787
in the presence or absence of 50 ng/ml VEGF or 10 ng/ml bFGF for 1 h at
4°C and then for 8 min at 37°C. VEGFR-2 was immunoprecipitated from
cell lysates. Western blot analysis was performed on immunoprecipitates
with an anti-phosphotyrosine antibody (upper panel) and a polyclonal
anti-VEGFR-2 antibody (lower panel). Three experiments were per-
formed and similar results were obtained.
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against a different peptide than the antibody used for
immunoprecipitation. A band of 200 kDa and a second
band of approximately 190 kDa were detected (Fig. 1),
which is consistent with our previous findings (Mandriota
et al., 1996; Mandriota and Pepper, 1997; Pepper and
Mandriota, 1998).
VEGFR Tyrosine Kinase Inhibitors Inhibit Angio-
genesis in Vivo. The VEGFR-2 tyrosine kinase inhibitors
(Table 1) were tested in an in vivo model of angiogenesis. In
this model, VEGF and bFGF induce growth of vascularized
tissue around a subcutaneous implant. The angiogenic re-
sponse is quantitated by measuring the weight and blood
content of this tissue. All compounds given in daily oral doses
for 6 days blocked VEGF-induced angiogenesis in a dose-
dependent manner (Table 2; Fig. 2). All of the compounds
also inhibited the response to bFGF to some extent, but the
dose-response curve was not linear for all compounds (Fig. 2).
The unexpected inhibition of bFGF-induced angiogenesis
prompted us to study this effect in more detail, using pure
cultures of endothelial cells and an in vitro model of angio-
genesis (Montesano and Orci, 1985).
VEGFR Tyrosine Kinase Inhibitors Inhibit Angio-
genesis in Vitro. We have shown previously that VEGF
family members and bFGF induce BME and BAE cells to
invade three-dimensional collagen gels as capillary-like,
tubular structures (in vitro angiogenesis). More precisely,
VEGF and bFGF induced invasion of BME cells (which
express VEGFR-1 and -2 and FGFR-1), whereas VEGF,
VEGF-C, and bFGF induced invasion of BAE cells (which
express VEGFR-1, -2, and -3 and FGFR-1) (Pepper et al.,
1992a, 1993b, 1998; Mandriota et al., 1996; Pepper and
Mandriota, 1998). In addition, bFGF and VEGF induced a
synergistic response in BME and BAE cells, VEGF-C po-
tentiated the effect of bFGF in BME cells, and VEGF and
VEGF-C had a synergistic effect on BAE cells (Pepper et
al., 1992a, 1995, 1998). Using a variety of VEGF mutants
that specifically bind VEGFR-1, -2, or -3 and neutralizing
anti-VEGFR-2 antibodies, we have observed that VEGF-
and VEGF-C (NC) in vitro angiogenic activities are
mediated by VEGFR-2 (J.-C. Tille and M. S. Pepper, manu-
script in preparation). We therefore investigated the effect
of the VEGFR-2 tyrosine kinase inhibitors listed in Table 1
on VEGF-, VEGF-C-, and bFGF- induced BME or BAE cell
collagen gel invasion.
All compounds completely inhibited VEGF-induced BME
and BAE cell invasion and VEGF-C-induced BAE cell inva-
sion. The inhibition was dose-dependent in both cells types
with a maximal effect from 1 M. bFGF-induced invasion
was reduced by 92% at 10 M in BME cells and by 88% at the
same concentration in BAE cells (Table 2; Figs. 3 and 4).
These findings are consistent with our in vivo results (Table
2; Fig. 2). Moreover, the synergistic angiogenic effect of
VEGF and bFGF was inhibited by 91% at 10 M (Fig. 4). No
overt cytotoxicity was observed with any of the VEGFR-2
kinase inhibitors used at concentrations of up to 10 M (Fig.
3).
Because the VEGFR-2 tyrosine kinase inhibitors have no
effect on FGFR-1, which is expressed by both BME and BAE
cells (Mandriota et al., 1996; Pepper and Mandriota, 1998;
Pepper et al., 1998), we hypothesized that bFGF-induced
angiogenesis may be mediated by the autocrine activity of
endogenous VEGF and/or VEGF-C in these cells.
TABLE 2
Inhibitory activity of VEGF receptor tyrosine kinase inhibitors on in
vitro and in vivo angiogenesis
Value represent the IC50 for in vitro assays and ED50 for in vivo assays calculated
from the means of at least three independent experiments.
ED50 In vivo
(mg/kg)
IC50 In vitro (M)
BAE BME
bFGF VEGF bFGF VEGF-C VEGF bFGF VEGF
PTK 787 30 21 0.027 0.032 0.057 0.08 0.009
AAC 789 9 26 1.102 0.035 0.016 0.035 0.0055
AAD 777 23 6 1.435 0.041 0.0117 0.012 0.009
Fig. 2. Inhibition of VEGF- and bFGF-induced angiogenesis in vivo by
VEGFR-2 tyrosine kinase inhibitors. Porous Teflon chambers (volume,
0.5 ml) filled with 0.8% w/v agar containing 20 U/ml heparin with or
without 2 g/ml VEGF or 0.3 g/ml bFGF were implanted subcutane-
ously on the dorsal flank of female mice. The mice were treated with
VEGFR-2 tyrosine kinase inhibitors at the indicated dose (p.o. once
daily) or vehicle. Five days after implantation, the mice were killed,
and the chambers were removed. The vascularized tissue growing
around the chamber was removed carefully and weighed, and the blood
content assessed by measuring hemoglobin. Results are shown as
percent inhibition of increase in blood content around the chamber.
Each experiment was performed with six animals per dose group, and
each dose was tested in at least two independent experiments.
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Effect of bFGF on Endogenous VEGF and VEGF-C
mRNA and Protein Expression in Endothelial Cells.
Based on the observation that bFGF increases VEGFR-2
expression at the levels of mRNA and total protein in BME
cells (Pepper and Mandriota, 1998), we hypothesized 1) that
BME and BAE cells may express VEGF and/or VEGF-C; 2)
that bFGF increases VEGF and VEGF-C in these cells; and
3) that the concomitant expression of VEGF, VEGF-C, and
VEGFR-2 promotes an autocrine loop of VEGFR-2 activation
in endothelial cells.
To assess the profile of expression of VEGF family mem-
bers by BME and BAE cells, total cellular RNAs from con-
fluent monolayers were analyzed by RNase protection. Both
cell lines were found to express the VEGF164 and VEGF120
isoforms, VEGF-B, and VEGF-C but not VEGF-D (Fig. 5).
RT-PCR analysis using a pair of oligonucleotide primers,
which are external to the alternative splicing region of bovine
VEGF, revealed four bands in the kidney (Fig. 6A), two of
which, corresponding in size to the VEGF164 and VEGF120
isoforms (411 or 279 bp, respectively) were also found in BME
and BAE cells. The size of the two larger bands (470 and
520 bp, respectively) in kidney may represent the bovine
counterparts of the VEGF189 and VEGF206 isoforms previ-
ously described in humans (for review, see Ferrara, 2001). No
bands were detected if RT was omitted (Fig. 5A), indicating
that the bands were not derived from contaminating genomic
DNA.
We next assessed whether bFGF affects expression of
VEGF-A, -B, and -C in our cells. RNase protection and semi-
quantitative RT-PCR analysis of BME and BAE cell RNAs
revealed that both the VEGF120 and the VEGF164 isoforms
were more abundant in bFGF-treated cells after 4 h and to a
lesser extent after 15 h incubation with bFGF (Figs. 5 and 6A
and data not shown). By RNase protection assay, VEGF164
mRNA was increased by 1.6- and 3.1-fold, respectively, in
BME and BAE cells treated with bFGF for 4 h, when nor-
malized to the internal control acidic ribosomal phosphopro-
tein P0 (Fig. 5). bFGF did not affect the relative proportion of
the two VEGF isoforms (Fig. 6A). After 4 h of exposure to
bFGF, VEGF-C mRNA was increased by 1.7- and 2.0-fold in
BME and BAE cells (Fig. 5 and 6C). bFGF did not increase
VEGF-B in BME or BAE cells, and VEGF-D was not induced
by bFGF in either cell line (Fig. 5 and 6B).
To assess the effect of bFGF on endogenous VEGF and
VEGF-C at the protein level, confluent monolayers of BME
and BAE cells were incubated with serum-free medium in
the presence or absence of bFGF for 8 h, and cell extracts
were analyzed by Western blot. Fig. 7A (upper panel) shows
the presence of a prominent band of 42 kDa, which corre-
sponds to the predicted molecular mass of bovine VEGF164
under nonreducing conditions. When recombinant human
VEGF165 was added to the incubation buffer at a 5-fold molar
excess over the primary antibody, the 42 kDa band was
undetectable, thus confirming its specificity (Fig. 7A, lower
panel). Similar results were obtained with BAE cells (data
not shown). No significant differences in the level of VEGF
protein were observed between bFGF-treated and untreated
BME or BAE cells, after 8 or 15 h of incubation (Fig. 7A and
data not shown). With respect to VEGF-C, a prominent band
at the expected size of 43 kDa could be detected in both
BME and BAE cells (Fig. 7B, upper panel). An additional,
higher molecular mass band was detected in BAE cells,
which may represent an unprocessed or partially processed
form of VEGF-C. After treatment with bFGF for 8 h, no
modulation was seen in the level of the 43 kDa VEGF-C
band in either cell line (Fig. 7B, upper panel). The specificity
of the band was assessed by replacing the anti-VEGF-C an-
tibody with normal rabbit serum (Fig. 7B, lower panel).
Taken together, these data demonstrate that bFGF in-
creases VEGF and VEGF-C mRNA expression in a transitory
manner in BME and BAE cells, without significantly altering
the expression of either gene at the protein level.
VEGF and VEGF-C Antagonists Inhibit bFGF-In-
duced Angiogenesis in Vitro. To assess the possibility
that the in vitro angiogenic effect of bFGF may be dependent
in part on an autocrine VEGF and/or VEGF-C loop, a chi-
meric molecule consisting of the extracellular domain of hu-
man VEGFR-1 fused to a fragment of the heavy chain of
human IgG1 (VEGFR-1-IgG), which is a potent inhibitor of
VEGF activity (Aiello et al., 1995; Shima et al., 1995), was
tested for its effect on bFGF-induced BME cell collagen gel
invasion. VEGFR-1-IgG, but not a CD4-human IgG1 fusion
protein, inhibited bFGF-induced in vitro angiogenesis in a
dose-dependent manner, with a maximal inhibition of 51% at
10 g/ml (Figs. 8 and 9A). Similarly, up to 48% inhibition was
observed with a neutralizing anti-human VEGF polyclonal
antibody, whereas preimmune rabbit -globulins had no ef-
fect (Figs. 8 and 9B). No toxicity was observed in VEGFR-1-
IgG- or anti-VEGF antibody-treated cells (Fig. 8). VEGF-
induced BME cell invasion was inhibited almost completely
by both VEGFR-1-IgG and the anti-human VEGF antibody
(Fig. 9, A and B). To assess the role of endogenous VEGF-C in
Fig. 3. Inhibition of VEGF-induced in vitro angiogenesis by PTK787.
Confluent monolayers of BME cells on three-dimensional collagen gels
were treated for 4 days with 30 ng/ml VEGF (c) or 10 ng/ml bFGF (e)
alone or in combination with 10 M PTK787 (d and f). The resulting
capillary-like tubular structures were viewed by phase-contrast micros-
copy. In b, in which the plane of focus is at the level of the surface of the
collagen gel, cells treated with 10 M PTK787 show no signs of cytotox-
icity (similar results were obtain with the other inhibitors). No invasion
occurred in untreated cultures (a). Bar, 75 m.
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bFGF-induced in vitro angiogenesis, a similar chimeric mol-
ecule (VEGFR-3-IgG) (Lee et al., 1996) was tested on bFGF-
induced BAE cell invasion. VEGFR-3-IgG inhibited bFGF-
induced in vitro angiogenesis in a dose-dependent manner,
with a maximal inhibition of 50% at 10 g/ml, whereas con-
trol IgGs had no effect (Fig. 9C). No toxicity was observed in
VEGFR-3-IgG-treated cells (data not shown). VEGFR-1-IgG
did not alter significantly VEGF-C-induced invasion, and or
VEGFR-3-IgG had no effect on invasion induced by VEGF,
thereby demonstrating that VEGF-C- induced angiogenesis
is not dependent on endogenous VEGF, and vice versa (data
not shown).
To assess directly the role of VEGFR-2 in bFGF-induced in
vitro angiogenesis, VEFGR-2 blocking antibodies (Witte et
al., 1998; Zhu et al., 1998) were added to the system. VEGF-
induced BME cell invasion was inhibited in a dose-dependent
manner by the two anti-human VEGFR-2 antibodies, p1C11
and 6.64, with a maximal inhibition of 99.0 and 99.9% at 20
g/ml (Fig. 10A and data not shown). Similarly, up to 99.5
and 98.5% inhibition was observed with p1C11 and 6.64 on
VEGF-induced BAE cell invasion (Fig. 10A and data not
shown). bFGF-induced BME cell collagen gel invasion was
inhibited partially by both antibodies with a maximal inhi-
bition of 48 and 49% at 20 g/ml of p1C11 and 6.64, respec-
tively (Fig. 10B). bFGF-induced BAE cell in vitro angiogen-
esis was inhibited by 23% with p1C11 and by 37.5% by 6.64
at 20 g/ml (Fig. 10C). The control isotope antibody, C225,
had no effect (Fig. 10B and 10C) and no toxicity was observed
in any of the antibody-treated cultures (data not shown).
These findings point to a role for VEGFR-2 in the in vitro
angiogenic effect mediated by bFGF in bovine endothelial
cells. We are aware that there are differences between
endothelial cells from different species and vascular beds
and that the VEGF/VEGFR-2 autocrine loop may not be
relevant to all cell types. Nonetheless, to extend this ob-
servation, we next assessed the effect of VEGFR-2 tyrosine
kinase inhibitors on endothelial cell functions that are
required for angiogenesis.
Fig. 4. Inhibition of in vitro angiogenesis by VEGFR-2 inhibitors. Confluent monolayers of BME cells on three-dimensional collagen gels were treated
with 10 ng/ml bFGF, 30 ng/ml VEGF, or both cytokines in combination, whereas BAE cells were treated with 3 ng/ml bFGF, 30 ng/ml VEGF, or 30
ng/ml VEGF-C. VEGFR-2 inhibitors were added at the concentrations indicated. Invasion was measured after 4 days and is expressed as percent
inhibition of sprouting induced by cytokines alone. Results are shown as the means  S.E.M. from at least three experiments per condition.
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The Role of VEGFR-2 Signaling in bFGF-Induced
Endothelial Cell Activation. Angiogenesis is dependent on
a triad of endothelial cell proliferation, migration, and extra-
cellular proteolytic activity, all of which are increased by
VEGF and bFGF (for review, see Pepper et al., 1996a, 1996b).
To assess the effect of VEGFR-2 tyrosine kinase inhibitors on
endothelial cell proliferation, low density cultures of VEGF-
and bFGF-treated BME cells were treated with the inhibitors
for 5 days. Cell number was increased by 53% in VEGF- and
280% in bFGF-stimulated cultures (Fig. 11A). In VEGF-
treated cultures, addition of the VEGFR-2 inhibitor AAC789
reduced BME cell number to baseline levels from 1 M (Fig.
11A). Likewise, bFGF-induced BME cell proliferation was
reduced markedly by AAC789 from 1 to 10 M, without
however reaching basal levels (Fig. 11A). Similar results
were obtained with the other VEGFR-2 tyrosine kinase in-
hibitors described in this paper (data not shown).
To assess the role of VEGFR-2 in VEGF- and bFGF-in-
duced plasminogen activator (PA) activity, BME cells were
incubated in the presence PTK787, alone or in combination
with VEGF or bFGF for 15 h, and cell extracts and culture
supernatants were analyzed by zymography. This revealed a
dose-dependent decrease in cell-associated uPA activity in
VEGF-stimulated BME cell extracts (Fig. 11B, upper panel).
In culture supernatants, a decrease in uPA and tPA (com-
plexed to PAI-1) was also observed (Fig. 11B, lower panel).
bFGF-induced uPA and tPA activity were decreased partially
by PTK787 in culture supernatants, but only at a 100-fold
higher concentration than that which was required for VEGF
(Fig. 11B, lower panel). PAI-1 activity, as assessed by reverse
zymography, was unaltered by PTK787 (data not shown).
To evaluate the importance of VEGFR-2 activation during
migration, VEGFR-2 kinase inhibitors were added to VEGF-
and bFGF-treated BAE cells in a modified Boyden chamber
assay. Migration was increased by 233% in VEGF- and 172%
in bFGF-stimulated cultures with a maximal effect at 100
and 10 ng/ml, respectively (Fig. 10C and data not shown). In
VEGF-treated cultures, addition of the VEGFR-2 inhibitor
AAD777 reduced BAE cell migration to baseline levels at 10
M (Fig. 11C). bFGF-induced migration was not altered sig-
nificantly by AAD777 (Fig. 11C).
To further evaluate the importance of VEGFR-2 activation
during bFGF-induced migration, we used a wounded mono-
layer model (Pepper et al., 1987). In this model, spontaneous
migration can be decreased by bFGF antagonists (demon-
strating the requirement for endogenous bFGF), can be stim-
ulated by exogenously added bFGF, and is unaffected by
exogenously added VEGF (Sato and Rifkin, 1988; Pepper et
al., 1993a; data not shown). To assess the effect of VEGF-R2
kinase inhibitors, confluent BME cell monolayers were
wounded mechanically and incubated for 15 h in the presence
or absence of the inhibitors. We observed no difference in the
number cells migrating across the wound edge (data not
shown), demonstrating that the VEGFR-2 inhibitors have no
effect on bFGF-dependent migration.
Taken together, our findings demonstrate that VEGF-in-
duced BME cell proliferation and PA activity can be inhibited
by VEGFR-2 antagonists from 1 and 0.1 M, respectively.
The inhibitory effect of the VEGFR-2 antagonists on bFGF-
induced proliferation occurred at a similar concentration,
whereas 100-fold higher concentrations of inhibitor were re-
quired for inhibition of PA activity when compared with
VEGF. Similarly, although the inhibitors were effective in
preventing migration induced by VEGF, bFGF-induced mi-
gration was unaffected. Therefore, among the bFGF-induced
endothelial cell functions that can be inhibited by VEGFR-2
antagonists, proliferation appears to be the most sensitive.
Discussion
In agreement with previous studies (Bold et al., 2000a;
Wood et al., 2000), we demonstrate in this report that
VEGFR-2 tyrosine kinase inhibitors block angiogenesis in-
duced by VEGF in vivo and in vitro. These inhibitors also
blocked VEGF-induced endothelial cell proliferation, pro-
tease (uPA and tPA) activity, and migration. Surprisingly
however, we found that these compounds also inhibited
bFGF-induced angiogenesis and endothelial cell proliferation
in the same models.
Because the VEGFR-2 tyrosine kinase inhibitors lack ac-
tivity against FGFRs, we explored the possibility that they
may act by interrupting an autocrine VEGF loop in cultured
endothelial cells (Seghezzi et al., 1998). To this end, we used
a well-characterized model of in vitro angiogenesis, in which
Fig. 5. Expression of VEGF family members by BME and BAE cells.
VEGF, VEGF-B, VEGF-C, and VEGF-D mRNA expression was studied
by RNase protection analysis in confluent monolayers of BME and BAE
cells. Purified 32P-labeled bovine cRNA probes were hybridized to hybrid-
ization mix (probe  h.m.), yeast tRNA (tRNA), or total RNA from BME
or BAE cells. Positive control: bovine lung for VEGF-A, VEGF-C, and
VEGF-D; bovine heart for VEGF-B. Parallel cultures were incubated for
4 h in the presence of 10 ng/ml bFGF.
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quiescent endothelial cells can be stimulated to invade a
three-dimensional collagen gel within which they form cap-
illary-like tubes (Montesano and Orci, 1985). We observed
that two different VEGF antagonists, namely VEGFR-1-IgG
(Aiello et al., 1995; Shima et al., 1995) and a neutralizing
polyclonal anti-VEGF antibody, but not CD4-IgG or preim-
mune IgG, inhibited bFGF-induced angiogenesis by approx-
imately 50%, and that this occurred in the absence of overt
cytotoxicity. VEGFR-3-IgG also inhibited bFGF-stimulated
BME cell collagen gel invasion by approximately 50%. Fur-
thermore, when blocking antibodies to VEGFR-2 were added
to the system, bFGF-induced invasion was inhibited in a
Fig. 6. Regulation of VEGF and
VEGF-C mRNA by bFGF in BME
and BAE cells. A, 2 g of total RNA
from adult bovine kidney or from
BME and BAE cells incubated for
the times indicated in the presence
of 10 ng/ml bFGF (F) or cytokine-
free medium (C) were combined
with random exanucleotides in the
presence of reverse transcriptase
(RT). Where indicated, RT was
omitted (RT). Samples or an
equivalent volume of H2O were
subjected to polymerase chain re-
action (upper panel). In a parallel
PCR reaction consisting an equal
volume of the same RT product
was amplified with a pair of prim-
ers of the bovine acidic ribosomal
protein P2. PCR products were
electrophoresed polyacrylamide
gels and stained with ethidium
bromide (lower panel). B and C,
confluent monolayers of BME cells
were incubated for 4 or 15 h in the
presence of 10 ng/ml bFGF (F) or
cytokine-free medium (C). At the
end of the incubation VEGF-B (B)
and VEGF-C (C) mRNA expres-
sion was assessed by RNase pro-
tection analysis. Purified 32P-la-
beled bovine cRNA probes (pr.)
were hybridized to hybridization
mix (pr.  h.m.), yeast tRNA
(tRNA), or total RNA from BME
cells. Bovine acidic ribosomal pro-
tein P0 was used as an internal
control.
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similar manner. These observations suggested that endoge-
nous VEGF and VEGF-C, acting in an autocrine manner, are
required for the in vitro angiogenic effect induced by exog-
enously added bFGF.
We next assessed whether our cells express endogenous
VEGF and VEGF-C, and if so, whether expression could be
modulated by exogenously added bFGF. We found that BME
Fig. 7. bFGF does not alter VEGF and VEGF-C protein levels in BME
and BAE cells. A, Western blot analysis of VEGF in confluent BME cell
monolayers incubated with 10 ng/ml bFGF or cytokine-free medium for
8 h. At the end of the incubation, cells were processed as described under
Materials and Methods. Upper panel, probed with anti-VEGF polyclonal
antibody; lower panel, antibody preincubated with rhVEGF165 protein. B,
Western blot analysis of VEGF-C in confluent BME and BAE monolayers
incubated with 10 ng/ml bFGF or cytokine-free medium for 8 h. At the
end of the incubation, cells were processed as described under Materials
and Methods. Upper panel, probed with anti-VEGF-C polyclonal anti-
body; lower panel, incubated with normal rabbit serum. This experiment
was repeated three times with similar results.
Fig. 8. Partial inhibition of bFGF-induced in vitro angiogenesis by Flt-
IgG and neutralizing anti-VEGF antibodies. Confluent monolayers of
BME cells on three-dimensional collagen gels were treated for 4 days with
10 ng/ml bFGF (a) or in combination with 10 g/ml VEGFR-1-IgG (c and
d), 30 g/ml neutralizing anti-human VEGF antibodies (f), 10 g/ml
CD4-IgG (b), or 30 g/ml preimmune -globulins (e). The resulting cap-
illary-like tubular structures were viewed by phase-contrast microscopy.
In c, the plane of focus is at the level of the surface of the collagen gel; cells
treated with 10 g/ml VEGFR-1-IgG show no sign of cytotoxicity. d, the
same field photographed beneath the surface monolayer. Arrows indicate
refringent lumina within endothelial cell cords that have invaded the
collagen gel. No invasion occurred in untreated cultures (data not shown).
Bar, 100 m.
Fig. 9. Partial inhibition of bFGF-induced in vitro angiogenesis by Flt-
IgG, neutralizing anti-VEGF antibodies, and Flt4-IgG. Confluent mono-
layers of BME cells on three-dimensional collagen gels were treated with
10 ng/ml bFGF alone or in combination with antagonists for 4 days, and
invasion, expressed as total additive sprout length (in micrometers), was
quantitated as described under Materials and Methods. A, VEGFR-1-IgG
(VR1-IgG) was added to VEGF- or bFGF-treated BME cells. VEGFR-1-
IgG (1 g/ml) inhibited VEGF-induced invasion by 96% and when added
at 10 g/ml, inhibited bFGF-induced invasion by 51%; CD4-IgG at 10
g/ml had no effect on invasion. B, neutralizing anti-VEGF antibodies
were added to VEGF- or bFGF-treated BME cells. The antibodies (30
g/ml) inhibited VEGF-induced invasion by 98% and bFGF-induced in-
vasion by 48%; preimmune -globulins (NRG) had no effect on invasion at
the same concentration. C, when added to 30 ng/ml VEGF-C-treated BAE
cells,10 g/ml VEGFR-3-IgG (VR3-IgG) inhibited invasion by 98%;
VEGFR-3-IgG was added to bFGF-treated BME cells at the concentra-
tions indicated, and inhibited bFGF-induced invasion by 50% at 10 g/ml;
control IgGs (anti-TNP) had no effect on invasion at the same concentra-
tion. Results are shown as mean total additive sprout length in microme-
ters  S.E.M. from at least three separate experiments per condition
(three wells per experiment). *, p  0.05; **, p  0.01; ***, p  0.001
(Student’s unpaired t test) when compared with invasion induced by
bFGF or VEGF alone.
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and BAE cells express VEGF, VEGF-B, and VEGF-C, but not
VEGF-D. Exogenously added bFGF induced a modest in-
crease in VEGF and VEGF-C mRNA at early (4 h) but not at
late (15 h) time points. Despite this increase, levels of VEGF
and VEGF-C protein were unaffected. Exogenously added
bFGF did not increase VEGF-B mRNA nor did it induce
expression of VEGF-D. Taken together with our observations
on in vitro angiogenesis, these findings strongly suggest that
collagen gel invasion induced by exogenously added bFGF is
dependent on endogenous VEGF and VEGF-C. In the present
study we also considered the possibility that bFGF may in-
duce trans-phosphorylation of VEGFR-2. No transphospho-
rylation was observed. However, we have demonstrated pre-
viously that bFGF strongly increases VEGFR-2 mRNA and
protein levels in BME and BAE cells (Pepper and Mandriota,
1998). This may imply that even though levels of endogenous
VEGF and VEGF-C are unaltered, signaling via VEGFR-2 is
increased in the presence of exogenous bFGF as a conse-
quence of an increase in VEGFR-2.
In contrast to the approximately 50% inhibition of bFGF-
induced invasion observed with VEGFR-1-IgG, neutralizing
anti-VEGF antibodies, and VEGFR-s blocking antibodies,
VEGFR-2 tyrosine kinase inhibitors decreased bFGF-in-
duced angiogenesis by approximately 90%. This difference
may reflect partial ligand-independent VEGFR-2 tyrosine
kinase activity in response to bFGF, because bFGF strongly
increases VEGFR-2 in our cells (Pepper and Mandriota,
1998). This possibility is not unprecedented, because many
Fig. 10. Partial inhibition of bFGF-induced in vitro angiogenesis by
blocking anti-VEGFR-2 antibodies. Confluent monolayers of BME and
BAE cells on three-dimensional collagen gels were treated with VEGF
(BME at 100 ng/ml and BAE at 50 ng/ml) or bFGF (BME at 10 ng/ml BAE
at 3 ng/ml) alone or in combination with neutralizing anti-VEGFR-2
antibodies for 4 days. A, anti-human VEGFR-2 antibodies p1C11 and
6.64 were added to VEGF-treated BME and BAE cells. p1C11 and 6.64
(20 g/ml) inhibited VEGF-induced BME and BAE cell invasion by 99%.
B, neutralizing anti-VEGFR-2 antibodies were added to bFGF-treated
BME cells. p1C11 and 6.64 (20 g/ml) inhibited bFGF-induced invasion
by 48 and 49%, whereas the isotope control antibody (C225) at the same
concentration had no effect on invasion. C, when added to bFGF-treated
BAE cells, p1C11 and 6.64 (20 g/ml) inhibited invasion by 23 and 37%,
respectively; the isotype control antibody (C225) had no effect on invasion
at the same concentration. Results are shown as mean total additive
sprout length in micrometers  S.E.M. from at least three separate
experiments per condition (three wells per experiment). *, p  0.05; **,
p  0.01; ***, p  0.005, ****, p  0.001 (Student’s unpaired t test) when
compared with invasion induced by bFGF alone.
Fig. 11. Partial inhibition of bFGF-induced endothelial cell proliferation
and PA activity but not migration by VEGFR-2 tyrosine kinase inhibitor.
A, BME cells were induced to proliferate with 100 ng/ml VEGF or 3 ng/ml
bFGF in the presence or absence of the indicated concentrations of ty-
rosine kinase inhibitors, and cell number was determined after 5 days.
This experiment was repeated twice in duplicate wells. Results are shown
as the mean cell number  S.E.M. B, BME cells were incubated with
indicated concentrations of PTK787 for 15 h, alone or in the presence of
30 ng/ml VEGF or 10 ng/ml bFGF. At the end of the incubation, cell
extracts (CE) and culture supernatants (SN) were subjected to zymogra-
phy. Two experiments were performed and similar results were obtained.
C, BAE cells were induced to migrate with 100 ng/ml VEGF or 10 ng/ml
bFGF with the indicated concentration of AAD777 for 24 h. Migrated cells
were quantitated and results are shown as migrated cell  S.E.M. (per-
centage of control) for at least of three wells per conditions. *, p  0.001
(Student’s unpaired t test) when compared with invasion induced by
VEGF alone.
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tyrosine kinase receptors are capable of ligand-independent
dimerization and phosphorylation. Furthermore, the stabil-
ity of the VEGFR-2 tyrosine kinase inhibitors is greater that
VEGFR-1-IgG and neutralizing anti-VEGF antibodies, which
implies that prolonged activity of the tyrosine kinase inhib-
itors can be expected once they have entered cells. Finally,
the partial inhibition seen with Flt-IgG and neutralizing
anti-VEGF antibodies may simply reflect invasion, which
occurs as a consequence of the direct effect of bFGF on FGFR
tyrosine kinases and which cannot be inhibited by these
antagonists. We have no explanation for the observation that
the IC50 values were greater in BAE than in BME cells.
The finding that endogenous endothelial cell VEGF and
VEGF-C account in part for the angiogenic effect of bFGF
implies that bFGF-induced angiogenesis per se is the conse-
quence of a “synergism” between these cytokines. In the same
way, because cultured endothelial cells produce their own
bFGF, angiogenesis induced by VEGF or VEGF-C could also
be considered as a form of “synergism.” In other words, al-
though bFGF or VEGF is angiogenic in vitro, both require the
presence of the other cytokine to mediate their effect. This
hypothesis is supported by the observation that inhibitory
antibodies to bovine bFGF completely prevent VEGF-in-
duced in vitro angiogenesis (Mandriota and Pepper, 1997).
Although it has been reported previously that bFGF stimu-
lates VEGF production in BAE cells and bovine capillary
endothelial cells (Seghezzi et al., 1998), in our experiments,
bFGF did not increase VEGF or VEGF-C protein in BME or
BAE cells. The reason for these differences are not known.
The finding that bFGF-induced invasion is dependent on
endogenous VEGF and VEGF-C and that bFGF increases
VEGFR-2, may explain, at least in part, why bFGF and
VEGF synergize in the induction of angiogenesis in vitro, and
why VEGF-C potentiates the effect of bFGF (Pepper et al.,
1992a, 1998; Goto et al., 1993). Thus, when bFGF and VEGF
or VEGF-C are tested in combination, the increase in
VEGFR-2 expression and its concomitant occupancy by both
endogenous and exogenous VEGF or VEGF-C may stimulate
angiogenesis to a greater extent than when either cytokine is
tested alone. This model also explains why at a constant dose
of bFGF, synergism is dependent on the amount of exog-
enously added VEGF or VEGF-C, and vice versa (Pepper et
al., 1992a, 1998). In the former case, the endogenous auto-
crine loop may sequester a constant number of VEGFR-2
molecules, thus allowing the remaining receptors, which are
also constant in number, to be activated proportionately to
the amount of exogenous VEGF or VEGF-C added; in the
latter case, at a constant dose of VEGF or VEGF-C, increas-
ing concentrations of bFGF would increase VEGFR-2 in a
dose-dependent manner, thus increasing VEGFR-2-mediated
signaling relative to the amount of bFGF added.
We have observed that the IC50 values required to block
VEGF-induced HUVE cell proliferation are lower than those
required for inhibition of kinase activity in the cell-free sys-
tem. It should be pointed out that the kinase assays are
performed under very artificial conditions using only the
kinase domain of the receptor and nonphysiological concen-
trations of ATP. The cellular assays represent more physio-
logical conditions of the receptor and may explain the differ-
ence in potency between the isolated kinase assays and the
cellular assays. Moreover, we and other investigators have
observed that many of these compounds are taken up avidly
into cells and are not readily washed out again (Mendel et al.,
2000). Hence the intracellular concentration may well be
higher than that in the medium. Finally, we cannot exclude
the possibility that the differences in potency between the
cell-based versus kinase assays reflect the fact that the in-
hibitors are acting via additional mechanisms in cell culture.
In summary, the findings that endothelial cells express
VEGF and VEGF-C and that the activity of exogenously
added bFGF is partially dependent on the activity of auto-
crine VEGF and VEGF-C may explain why VEGFR-2 antag-
onists have the capacity to inhibit partially bFGF-induced
angiogenesis in vivo and in vitro. The potential in vivo inhib-
itory effect of VEGFR-2 kinase inhibitors on a paracrine
VEGF and/or VEGF-C loop between fibroblasts/smooth mus-
cle cells and endothelial cells was not explored in our studies.
Nonetheless, we hypothesize that in vivo, bFGF-induced an-
giogenesis may be mediated, in part, either by autocrine or
paracrine VEGF, the former being released by endothelial
cells, and the latter by fibroblasts or smooth muscle cells.
This implies that the therapeutic applications of VEGFR-2
tyrosine kinase inhibitors are not limited to settings in which
angiogenesis is induced by VEGF but can also be widened to
settings in which bFGF is the primary or costimulus.
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Abstract
Angiogenesis and lymphangiogenesis are regulated by members of the vascular endothelial growth factor (VEGF) family of cytokines,
which mediate their effects via tyrosine kinase VEGF receptors -1, -2, and -3. We have used wild-type and mutant forms of VEGFs -A,
-B, and -C, a pan-VEGFR tyrosine kinase inhibitor (SU5416) as well as neutralizing anti-VEGFR-2 antibodies, to determine which VEGF
receptor(s) are required for bovine endothelial cell invasion and tube formation in vitro. This was compared to the ability of these cytokines
to induce expression of members of the plasminogen activator (PA)-plasmin system. We found that cytokines which bind VEGFR-2 (human
VEGF-A, human VFM23A, human VEGF-CNC, and rat VEGF-C152) induced invasion, tube formation, urokinase-type-PA, tissue-type-
PA, and PA inhibitor-1, invasion and tube formation as well as signaling via the MAP kinase pathway were efficiently blocked by SU5416
and anti-VEGFR-2 antibodies. In contrast, cytokines and mutants which exclusively bind VEGFR-1 (human VFM17 and human VEGF-B)
had no effect on invasion and tube formation or on the regulation of gene expression. We were unable to identify cytokines which selectively
stimulate bovine VEGFR-3 in our system. Taken together, these findings point to the central role of VEGFR-2 in the angiogenic signaling
pathways induced by VEGF-CNC and VEGF-A.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Angiogenesis, the formation of new capillary blood ves-
sels, is an absolute requirement for the establishment of a
vascular supply in both normal and neoplastic tissues. Dur-
ing angiogenesis, previously quiescent endothelial cells are
stimulated to degrade their basement membrane and to
invade the surrounding stroma, initially as solid endothelial
cell cords. Later, these cords develop a lumen, deposit a new
basement membrane, and establish an intimate association
with perivascular cells, including pericytes and smooth
muscle cells. Several molecules affect one or more endo-
thelial cell functions involved in these processes. Many are
polypeptide growth factors, among which the fibroblast
growth factor (FGF), vascular endothelial growth factor
(VEGF), and angiopoietin (Ang) families are the best char-
acterized [1].
VEGF-A is an endothelial cell-specific mitogen, which
acts through two tyrosine kinase receptors, VEGFR-1/Flt
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and VEGFR-2/Flk-1/KDR, whose expression is restricted to
endothelial cells, monocytes, and hematopoietic precursors.
Targeted disruption of either the VEGFR-1 or the VEGFR-2
results in lethal embryonic vascular and/or hematopoietic
abnormalities. Similar defects have been described in mice
lacking a single copy of the VEGF-A gene, which indicates
a crucial dose-dependent requirement for VEGF-A during
early development [2]. VEGF-C, a protein with structural
homology to VEGF-A, was the first VEGFR-3/Flt-4 ligand
to be described. VEGFR-3 is widely expressed in embry-
onic endothelium, but in postnatal life becomes restricted to
lymphatic endothelial cells and some venules [3]. Based on
its expression profile and binding to VEGFR-3, VEGF-C
has been implicated in the development of the lymphatic
system, and tissue-specific overexpression of VEGF-C in
the mouse results in a specific lymphangiogenic effect [4,5].
However, the role of VEGF-C and VEGFR-3 is not re-
stricted to lymphangiogenesis. First, targeted inactivation of
the VEGFR-3 gene results in embryonic lethal vascular
defects, prior to the emergence of lymphatic vessels [6].
Second, VEGFR-3 is reexpressed in blood vessels of some
tumors, where it appears to be important for blood vessel
integrity [7,8]. Third, VEGF-C can induce angiogenesis
under certain circumstances [9,10], which could be due in
part to its capacity to bind to and activate VEGFR-2, in
addition to VEGFR-3 [11]. Interestingly, both VEGF-A and
VEGF-C have been reported to synergize with FGF-2 in the
induction of angiogenesis in vitro [12].
We have previously shown that VEGF and FGF family
members induce bovine microvascular and aortic endothe-
lial cells (BME and BAE cells) to invade three-dimensional
collagen gels within which they form capillarylike tubular
structures (in vitro angiogenesis). VEGF-A and FGF-2 in-
duced invasion of BME cells (which express VEGFRs -1
and -2 and FGFR-1) while VEGF-A, VEGF-CNC, and
FGF-2 induced invasion of BAE cells (which express VEG-
FRs -1, -2, and -3 and FGFR-1) [12–15]. In addition, FGF-2
and VEGF-A induced a synergistic response in BME and
BAE cells, VEGF-CNC potentiated the effect of FGF-2 in
BME cells, and VEGF-A and VEGF-CNC had a syneg-
istic effect on BAE cells [12,15,16]. Using a variety of
VEGF mutants that specifically bind different VEGFRs as
well as a pan-VEGFR tyrosine kinase inhibitor and neutral-
izing anti-VEGFR-2 antibodies, in the present studies we
have observed that the in vitro angiogenic activity of
VEGF-CNC and VEGF-A are mediated by VEGFR-2.
Experimental procedures
Reagents
Recombinant human FGF-2 (155 amino acid form) was
kindly provided by Dr P. Sarmientos (Farmitalia Carlo
Erba, Milan, Italy). Recombinant human VEGF-A (165
amino acid homodimeric isoform) was purchased from
Pepro Tech Inc. (Rocky Hill, NJ). VFM17 and VFM23A
were prepared as previously described [17,18]. Recombi-
nant human VEGF-CNC, human VEGF-C-cys1563ser
(VEGF-C156), rat VEGF-C-cys1523ser (VEGF-C152), hu-
man VEGF-B167, and VEGF-B186 were prepared as previ-
ously described [11,19–23]. VEGF-B167 and VEGF-B186
were used with or without polymyxin-B (Calbiochem, La
Jolla, CA, USA) at 10 g/ml to inhibit contaminating lipo-
polysaccharide (LPS). Anti-VEGFR-2 antibodies (IMC-
1C11, MAB6.64, DC101) and an isotype control for IMC-
1C11 (IMC-C225) were prepared and characterized as
previously described [24–27]. The pan-VEGFR tyrosine
kinase inhibitor, SU5416, was synthesized as previously
described [28].
Cell culture
Bovine adrenal cortex-derived microvascular endothelial
cells (BME) [29] were grown in minimal essential medium,
alpha modification (MEM - Gibco BRL, Life Technolo-
gies, Paisley, Scotland), supplemented with 15% heat-inac-
tivated donor calf serum (DCS) (Gibco), penicillin (110
U/ml), and steptomycin (110 g/ml). Bovine aortic endo-
thelial cells (BAE) [30] were cultured in low glucose Dul-
becco’s modified minimal essential medium (DMEM)
(Gibco) supplemented with 10% DCS and antibiotics.
In vitro angiogenesis assay
The in vitro angiogenesis assay was performed as de-
scribed [31]. BME and BAE cells were seeded onto 500 l
three-dimensional rat Type I collagen gels in 16 mm tissue
culture wells, at 1.0  105 cells/well in 500 l MEM 
2%DCS. Upon reaching confluence, the cells were treated
with cytokines, antibodies, or SU5416. Medium, cytokines,
and antagonists were renewed every 2–3 days, and cultures
were photographed under phase contrast microscopy using a
Nikon Diaphot TMD inverted photomicroscope (Nikon, To-
kyo, Japan) after 2–7 days. Quantitation was performed as
described [15]. Results are shown as the mean additive
sprout length  SEM (in m) for at least three experiments
per condition. Mean values were compared using Student’s
unpaired t test, and a significant P value was taken as 
0.05.
RNA purification, Northern blot analysis, and RNase
protection assay
Total cellular RNA was purified using Trizol reagent
(Invitrogen), according to the manufacturer’s instructions.
Northern blot analyses were performed as previously de-
scribed [16]. Briefly, 32P-dUTP-labeled cRNA probes were
prepared from bovine uPA, human tPA, bovine uPAR, and
bovine PAI-1 cDNAs. Autoradiograms were scanned with a
Laser ScanJet Ilex Instrument (Hewlett Packard Co., Palo
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Alto, CA, USA) and bands were quantitated using Image-
Quant 3.3 (Molecular Dynamics).
VEGF-receptor tyrosine kinase assays
IC50 values for SU5416 were determined using proteins
composed of GST fused to the cytoplasmic domains of
human VEGFR-1, VEGFR-2, and VEGFR-3 that were ex-
pressed in SF9 cells and purified on a glutathione column.
As a substrate, the random copolymer, poly-(Glu:Tyr 4:1)
was immobilized in 96-well plates. Buffer containing ATP
(at twice the Km for the enzyme), divalent metal ions, and
various concentrations of SU5416 were added to each well.
The kinase reaction was initiated by addition of the enzyme.
The amount of phosphate transferred to the substrate was
then detected by ELISA using PY99-HRP conjugate (SC-
7020, Santa Cruz) and 2,2-azino-bis(3-ehtylbenzthiazoline-
6-sulfnonatci acid). IC50 values were then calculated by
linear regression analysis of the percentage inhibition.
Immunoprecipitation/Western blotting
Confluent BME and BAE cell monolayers were incu-
bated in reduced serum (2% DCS) for 16–24 h. VEGFR-2
phosphorylation assays were performed as follows. After
incubation with different concentrations of SU5416 for 1 h,
cells were stimulated with VEGF-A, VEGF-CNC, VEGF-
C156, or VEGF-C152 for 8 min and lysed with 1 ml lysis
buffer containing 50 mM Hepes, 150 mM NaCl, 10% glyc-
erol, 0.5% Triton X-100, 100 mM PMSF, 1 mM sodium
vanadate, and 2 g/ml leupeptin and aprotinin. VEGFR-2
was immunoprecipitated from cell lysates using a poly-
clonal antibody (SC-504, Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA). Immunoprecipitates were boiled for
3 min in the presence of 100 mM DTT, run in a 6% SDS
polyacrilamide gel, and transferred to a polyvinilidene di-
fluride membrane (BioRad, Hercules, CA, USA). Western
blot analysis was performed with an anti-phosphotyrosine
antibody (#05-321, Upstate Biotechnology Inc., Lake
Placid, NY, USA or SC-7020HRP, Santa Cruz). The mem-
brane was then stripped and reprobed with anti-VEGFR-2
antibodies (SC-505 or SC-315, Santa Cruz) to assess protein
loading in each well. To examine VEGF-A and VEGF-
CNC induced phosphorylation of ERK, aliquots of cell
lysates were subjected to electrophoresis followed Western
blotting with an anti-phospho-ERK antibody (SC-7383,
Santa Cruz or #9106, New England BioLabs Inc., Beverly,
MA, USA). The membrane was then stripped and reprobed
with an anti-ERK antibody (#9102, New England BioLabs
Inc. or SC-93 and SC-154, Santa Cruz) to assess protein
loading in each well. VEGFR-3 phosphorylation assays
were performed as follows. After incubation with different
concentration of SU5416 for 1 h, cells were stimulated with
VEGF-A, VEGF-CNC, VEGF-C156, or VEGF-C152 for 8
min and lysed. VEGFR-3 was immunoprecipitated from
cell lysates using a polyclonal anti-VEGFR-3 antibody (SC-
637, Santa Cruz). Western blot analysis was performed with
an anti-phosphotyrosine antibody (#05-321, Upstate Bio-
technology Inc.) The membrane was then stripped and re-
probed with the same anti-VEGFR-3 antibody to assess
protein loading in each well.
Results
VEGFR-2 is sufficient to mediate VEGF-CNC- and
VEGF-A-induced invasion and tube formation in vitro
The ability of VEGF-A to signal through VEGFR-2 has
been well documented. In order to assess the role of VEG-
Fig. 1. Induction of angiogenesis in vitro by a VEGFR-2-selective ligand.
Confluent BME (A) and BAE (B) cell monolayers on three-dimensional
collagen gels were treated with VFM17 or VFM23A at the indicated
concentrations, or with VEGF-A (30 ng/ml). After 2–4 days, invasion,
expressed as total additive sprout length (in m  SEM), was quantitated.
Results are from at least three separate experiments per condition. *P 
0.005, **P  0.001, when compared to cells were grown in the absence of
cytokines (Student’s unpaired t test). (C) Confluent BAE cell monolayers
on three-dimensional collagen gels were treated with FGF-2 (3 ng/ml),
VEGF-A (30 ng/ml), both cytokines (F/VA), or FGF-2 combined with
VEGF receptor-specific ligands (VFM17 or VFM23A) at the indicated
concentrations. After 2–4 days, invasion, expressed as total additive sprout
length (in m  SEM), was quantitated. Results are from at least three
separate experiments per condition. *P  0.005, **P  0.001 when
compared to cells grown in the presence of FGF-2, and ¶P  0.005, ¶¶P
 0.001 when compared to cells grown in the combined presence of FGF-2
and VEGF-A (Student’s unpaired t test).
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Fig. 2. In vitro angiogenesis induced by VEGF-CNC and VEGF-C152. Confluent BME cell monolayers on three-dimensional collagen gels were treated for 4 days
with VEGF-CNC (30 ng/ml), FGF-2 (10 ng/ml), or both cytokines in combination. Confluent BAE cell monolayers on three-dimensional collagen gels were
treated for 4 days with VEGF-A (100 ng/ml), VEGF-CNC (100 ng/ml), or VEGF-C152 (100 ng/ml). Phase contra´st views of BME and BAE control
untreated monolayer; BME cells treated with FGF-2; lack of response after exposure to VEGF-CNC on BME cells; potentiating effect of VEGF-CNC
on FGF-2-induced invasion; BAE cells treated with VEGF-A; the same response induced by VEGF-CNC and VEGF-C152 on BAE cells. Bar  50 m.
FRs -1 and -2 in VEGF-A-induced endothelial cell invasion
and tube formation in our in vitro system, we used ligands
which display selectivity for VEGFRs -1 and -2. VFM17
and VFM23A were obtained by alanine-scanning mutagen-
esis of VEGF-A and specifically bind to VEGFRs -1 and -2,
respectively [17,18]. Like VEGF-A, VFM23A induced
BME and BAE cell collagen gel invasion and tube forma-
tion in a dose-dependent manner (Fig. 1A and B). VFM17
on the other hand lacked invasion-inducing activity (Fig. 1A
and B). Similarly, VEGF-B167, VEGF-B186, and PIGF,
which specifically bind VEGFR-1, did not induce invasion
in either cell type (data not shown). We have previously
reported that coaddition of VEGF-A and FGF-2 induce a
synergistic invasive response in BME and BAE cells (Fig.
1C). When VFM23A or VFM17 were added to FGF-2-
treated BME and BAE cells, a synergistic effect on invasion
was only observed with VFM23A (Fig. 1C and data not
shown). The synergistic effect induced by the coaddition of
VFM23A and FGF-2 was greater than that induced by
VEGF-A and FGF-2 (Fig. 1C). This finding may reflect a
possible role for VEGFR-1 as a “sink” for VEGF-A in our
cells [32]. No potentiating effect was observed with the
coaddition of VEGF-B167, VEGF-B186, or PIGF together
with FGF-2 in BME and BAE cells (data not shown). These
results demonstrate that VEGFR-2 mediates VEGF-A-in-
duced in vitro angiogenesis as well as the synergism with
FGF-2 in BME and BAE cells.
We have previously reported that the proteolytically pro-
cessed form of VEGF-C (21 kDa, also known as VEGF-
CNC), which binds to and activates VEGFRs -2 and -3
[11], induces BAE but not BME cell collagen gel invasion
[12] (Figs. 2 and 3A). To determine whether the in vitro
activity of VEGF-CNC might be mediated by VEGFR-3,
we compared its activity to VEGF-C156 which selectively
induces phosphorylation of VEGFR-3 [21]. VEGF-CNC
induced BAE cell collagen gel invasion in a manner iden-
tical to that seen with VEGF-A (Figs. 2 and 3B), whereas
VEGF-C156 had no effect (Fig. 3B). We have previously
reported that the coaddition of VEGF-CNC and FGF-2 to
BME and BAE cells induced a potentiating or synergistic
invasive response [12]. In the present studies, we observed
that when VEGF-CNC or VEGF-C156 were coadded with
FGF-2, a potentiating (BME cells) or synergistic (BAE
cells) response was observed only with VEGF-CNC and
not with VEGF-C156 (Figs. 2 and 3A). Although the com-
bination of VEGF-CNC and VEGF-A also induces a syn-
ergistic response in BAE cells [12], when VEGF-A and
VEGF-C156 were coadded, a synergistic response was not
observed (Fig. 3B). These results suggest that in our system,
VEGFR-2 mediates the synergistic invasive response in-
duced by VEGF-CNC in combination with either FGF-2
or VEGF-A.
The ineffectiveness of VEGF-C156 in our model
prompted us to test another selective agonist for VEGFR-3,
namely rat VEGF-C152 [20]. Surprisingly, VEGF-C152 in-
duced BAE cell collagen gel invasion in a dose-dependent
manner reaching saturation at 100 ng/ml. This response was
identical to that seen with VEGF-CNC (Figs. 2 and 3C).
Furthermore, as previously demonstrated for VEGF-CNC
(Fig. 2), VEGF-C152 had no effect on BME cells (data not
shown).
Induction of components of the PA-plasmin system by
VEGFR-2 ligands
Expression of members of the endothelial PA-plasmin
system is modulated by a number of factors including
VEGFs -A, -B, and -C and FGF-2 [12,23,33]. In the present
study, we assessed whether VEGF family members induce
Fig. 3. Quantitation of BME and BAE cell in vitro angiogenesis. (A)
Confluent monolayers of BME cells on three-dimensional collagen gels
were treated with VEGF-A (30 ng/ml, V-A), VEGF-CNC (30 ng/ml,
V-CNC), VEGF-C156 (30 ng/ml, V-C156), or FGF-2 (10 ng/ml, F), alone
or in combination as indicated. (B) Confluent BAE cell monolayers on
three-dimensional collagen gels were treated with FGF-2 (3 ng/ml, F),
VEGF-A (30 ng/ml, V-A), VEGF-CNC (30 ng/ml, V-CNC), or VEGF-
C156 (30 ng/ml, V-C156), alone or in combination as indicated. (C) Con-
fluent BAE cell monolayers on three-dimensional collagen gels were
treated with VEGF-CNC or VEGF-C152 at the indicated concentrations.
After 4 days, invasion, expressed as total additive sprout length (in m 
SEM), was quantitated. Results are from at least three separate experiments
per condition. *P  0.05, **P  0.005 when compared with cells grown
in the absence of cytokines, ¶P  0.05, ¶¶P  0.025, ¶¶¶P  0.001 when
compared with cells grown in the presence of FGF-2 or VEGF-A (Stu-
dent’s unpaired t test). After 4 days, invasion was quantitated. Results are
from at least three separate experiments per condition.
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Fig. 4. Northern blot analysis of PA, uPAR, and PAI-1 mRNA levels in BME and BAE cells. (A) Replicate filters containing total cellular RNA (5 g/lane)
from confluent BAE cell monolayers incubated for 4 h with the indicated cytokines (VEGFs at 50 ng/ml, FGF-2 at 3 ng/ml) were hybridized with 32P-labeled
bovine uPA, bovine uPAR, human tPA, or bovine PAI-1 cRNA probes. Methylene blue staining reveals 28S and 18S rRNAs and demonstrates uniformity
of loading and RNA integrity. (B) Quantitation of uPA, uPAR, tPA, and PAI-1 mRNA levels in BAE and BME cells incubated with the indicated cytokines
for 4 and 24 h. The graphs show values obtained by scanning densitometry (normalized with respect to the 28S rRNA)  SEM from three independent
experiments. An arbitrary value of 1 was assigned to controls.
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Fig. 5. VEGFR and ERK phosphorylation patterns induced by VEGF-A, VEGF-CNC, and VEGF-C mutants—effect of SU5416. (A) BAE cells were
stimulated with VEGF-A (50 ng/ml) in the absence or presence of 1 or 10 M SU5416. Upper panels: VEGFR-2 was immunoprecipitated from cell lysates
with an anti-VEGFR-2 antibody. The Western blot of these immunoprecipitates was probed with an phosphotyrosine (anti-pTyr) antibody and anti-VEGFR-2
antibody. Lower panels: The Western blot was probed with an anti-phospho-ERK antibody. The blot was stripped and reprobed for total ERK protein using
an anti-ERK antibody. (B) BAE cells were stimulated with VEGF-CNC (50 ng/ml) in the absence or presence of 1 or 10 M SU5416, VEGF-A (50 ng/ml),
or VEGF-C156 (50 ng/ml). Upper panels: Western blot analysis was performed on immunoprecipitated VEGFR-2 with an anti-pTyr antibody and an
anti-VEGFR-2 antibody. Lower panels: The Western blot was probed with anti-phospho-ERK antibody, stripped, and reprobed for total ERK protein using
an anti-ERK antibody. (C) BAE cells were stimulated with VEGF-CNC (100 ng/ml) in the absence or presence of 10 M SU5416. Western blot analysis
was performed on immunoprecipitated VEGFR-3 with an anti-pTyr antibody and an anti-VEGFR-3 antibody. (D) BAE cells were stimulated with
VEGF-CNC (100 ng/ml), VEGF-A (100 ng/ml), or VEGF-C156 (100 ng/ml). Western blot analysis was performed on immunoprecipitated VEGFR-3 with
an anti-pTyr antibody and an anti-VEGFR-3 antibody. (E) BAE cells were stimulated with VEGF-A (100 ng/ml), VEGFR-CNC (100 ng/ml), or VEGF-C152
(100 ng/ml). Western blot analysis was performed on immunoprecipitated VEGFR-2 with an anti-pTyr antibody and an anti-VEGFR-2 antibody. (F) BAE
cells were stimulated with VEGF-CNC (100 ng/ml) or VEGF-C152 (100 ng/ml). Western blot analysis was performed on immunoprecipitated VEGFR-3
with an anti-pTyr antibody and an anti-VEGFR-3 antibody.
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PAs via VEGFRs -1, -2, or -3. Confluent monolayers of
BME and BAE cells were incubated with VEGF-B167,
VEGF-B186, VEGF-A, VFM17, VFM23A, VEGF-CNC,
VEGF-C156, or FGF-2 for 4 and 24 h. Northern blot analysis
of total cellular RNAs from BAE cells treated for 4 h
revealed an increase in the steady state levels of uPA,
uPAR, tPA, and PAI-1 mRNA by VEGF-A, VFM23A,
VEGF-CNC, and FGF-2 (Fig. 4A), while specific ligands
for VEGFR-1 and VEGFR-3 had no effect (Fig. 4A). A
quantitative estimate of Northern blot analysis performed on
BME and BAE cells at 4 and 24 h revealed a marked
transitory increase in tPA and PAI-1 mRNA by VEGFR-2
ligands with a lesser effect on uPA and uPAR (Fig. 4B).
These results suggest that VEGFs -CNC and -A induce
uPA, tPA, uPAR, and PAI-1 mRNAs via activation of
VEGFR-2.
In order to further assess the role of VEGFR-2 and
VEGFR-3 in invasion and tube formation, we used a pan
VEGFR tyrosine kinase inhibitor, SU5416 [28].
VEGFR-2 signaling is necessary for VEGF-CNC and
VEGF-A-induced in vitro angiogenesis
SU5416 is a pan-VEGFR inhibitor which inhibits human
VEGFR-1 (IC50  0.09 M  0.03, n  4) more than
VEGFR-2 (IC50  1.3 M  0.8, n  14) or VEGFR-3
(IC50  0.65 M  0.24, n  5). In order to assess the
effect of SU5416 on VEGF-A and VEGF-CNC-induced
VEGFR-2 phosphorylation and signaling, BAE and BME
cells were stimulated with VEGF-A, VEGF-CNC, or
VEGF-C156 in the absence or presence of 1 or 10 M
SU5416. The phosphorylation of VEGFR-2 and ERK was
then examined by Western blotting of VEGFR-2 immu-
noprecipitates or whole cell extracts, respectively.
VEGF-A and VEGF-CNC induced phosphorylation of
VEGFR-2 in both cell types, whereas VEGF-C156 had no
effect (Fig. 5 and data not shown). The induction of
VEGFR-2 phosphorylation by VEGF-A was much
weaker in BME than in BAE cells (data not shown).
Furthermore, VEGF-CNC was less potent than
VEGF-A in the induction of VEGFR-2 phosphorylation
in BAE cells (Fig. 5B). SU5416 completely inhibited the
phosphorylation of VEGFR-2 in both cell types at 10
M, with partial inhibition at 1 M in BAE cells (Fig.
5A and B and data not shown). To determine whether
SU5416 affected intracellular signaling downstream of
VEGFR-2, VEGF-A, or VEGF-CNC-stimulated phos-
phorylation of ERK was examined. As observed for
VEGFR-2, VEGF-A, and VEGF-CNC induced ERK
phosphorylation, with an apparently greater response in
BAE cells (Fig. 5A and B and data not shown). At 10
M, SU5416 significantly reduced ERK phosphorylation
in both cell lines (Fig. 5A and B and data not shown).
Only a modest inhibition of ERK phosphorylation was
observed with 1 M SU5416 in BAE cells (Fig. 5A and
B). The poor inhibition of ERK phosphorylation at 1 M
is likely to result from the fact that SU5416 is only able
to partially inhibit VEGFR-2 phosphorylation at this con-
centration.
In order to assess whether SU5416 affected VEGFR-3
phosphorylation, BAE cells were stimulated with VEGF-
CNC in the absence or presence of 10 M SU5416.
SU5416 completely inhibited the phosphorylation of
VEGFR-3 at 10 M (Fig. 5C). These results confirm the
pan-VEGFR inhibitory activity of SU5416 (see above).
SU5416 was recently reported to inhibit additional tyrosine
kinase receptors such as FLT-3 [34].
The difference in in vitro angiogenic activity in our
model between the two VEGFR-3 selective ligands, VEGF-
C156 and VEGF-C152, prompted us to determine whether
they are both capable of inducing VEGFR-3 phosphoryla-
tion. BAE cells were stimulated with VEGF-CNC, VEGF-
C156, and VEGF-A as a negative control. VEGF-CNC
induced VEGFR-3 phosphorylation, whereas VEGF-C156
and VEGF-A had no effect (Fig. 5D). The profile of bovine
VEGF receptor activation by VEGF-C152 was then deter-
Fig. 6. SU5416 inhibits VEGF-A and VEGF-CNC-induced in vitro an-
giogenesis. Confluent monolayers of BME cells on three-dimensional col-
lagen gels were treated with VEGF-A (30 ng/ml), while BAE cells were
treated with VEGF-A (30 ng/ml) or VEGF-CNC (30 ng/ml). SU5416 was
added at the indicated concentrations. After 4 days, invasion, expressed as
total additive sprout length (in m  SEM), was quantitated. Results are
from at least three separate experiments per condition. *P  0.05, **P 
0.005, ***P  0.001 when compared with cells grown in the absence of
inhibitor (Student’s unpaired t test).
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mined. We observed that VEGF-C152 and VEGF-CNC
induced phosphorylation of both bovine VEGFR-2 and
VEGFR-3 (Fig. 5E and F). VEGF-CNC and VEGF-C152
appeared to be less potent than VEGF-A in the induction of
VEGFR-2 phosphorylation (Fig. 5E) but had the same ef-
ficacy on VEGFR-3 (Fig. 5F).
VEGF-A-induced BME and BAE cell collagen gel
invasion was blocked by SU5416 in a dose-dependent
manner, with complete inhibition at 1 M in BME cells
and 10 M in BAE cells (Fig. 6A and B). These results
are in agreement with the inhibition observed in the
VEGF receptor phosphorylation assay (Fig. 5). VEGF-
CNC-induced BAE cell in vitro angiogenesis was also
inhibited in a dose-dependent manner, with complete
inhibition at 1 M SU5416 (Fig. 6C). In order to specif-
ically inhibit VEGFR-2 we employed blocking antibodies
to VEGFR-2 [25,26].
Anti-VEGFR-2 antibodies inhibit VEGF-CNC and
VEGF-A-induced in vitro angiogenesis
Anti-VEGFR-2 antibodies inhibited VEGF-A-induced
BME cell invasion in a dose-dependent manner. Two mono-
clonal anti-human VEGFR-2 antibodies, IMC-1C11 and
MAB6.64, inhibited invasion by 99.0% and 99.9% at 20
g/ml, respectively, whereas a control isotype antibody,
IMC-C225, had no effect (Fig. 8A). A blocking anti-mouse
VEGFR-2 antibody, DC101, which does not cross react
with human VEGFR-2 [24] had no effect on VEGF-A-
induced BME cell invasion (Fig. 8A). Similarly, up to
99.5% and 98.5% inhibition was observed with IMC-1C11
and MAB6.64 on VEGF-A induced BAE cell invasion
(Figs. 7 and 8B). On the other hand, VEGF-CNC-induced
BAE cell invasion was only partially inhibited by IMC-
1C11 and MAB6.64 antibodies—63.2% and 58.7% at 5 to
Fig. 8. Quantitation of anti-VEGFR-2 antibody inhibition of in vitro angiogenesis. Confluent BME and BAE cell monolayers on three-dimensional collagen
gels were treated with VEGF-A (BME at 100 ng/ml, BAE at 50 ng/ml) or VEGF-CNC (BAE at 50 ng/ml) in the presence or absence of anti-human
VEGFR-2 monoclonal antibodies (IMC-1C11, MAB6.64), a rat anti-mouse VEGFR-2 monoclonal antibody (DC101), or an isotope control (IMC-C225), at
the indicated concentrations. After 4–7 days, invasion, expressed as total additive sprout length (in m  SEM), was quantitated. (A) IMC-1C11 and
MAB6.64 inhibited VEGF-A-induced BME cell invasion by 99.0% for both antibodies at 20 g/ml, whereas DC101 and IMC-C225 had no effect on invasion
at the same concentration. (B) When added to VEGF-A-treated BAE cells, IMC-1C11 and MAB6.64 inhibited invasion by 99.5% and 98.5% respectively,
while IMC-C225 had no effect on invasion. (C) IMC-1C11 and MAB6.64 inhibited VEGF-CNC-induced BAE cell invasion by 67.7% and 64.8%,
respectively, whereas the isotope control antibody (IMC-C225) had no effect on invasion. (D) IMC-1C11 inhibited VEGF-C152-induced BAE cell invasion
by 61.5%, whereas IMC-C225 had no effect. Results are from at least three separate experiments per condition. *P  0.001, **P  0.005, when compared
with values in the absence of antibody (Student’s unpaired t test).
Fig. 7. Inhibition of VEGF-A and VEGF-CNC-induced in vitro angiogenesis by blocking antibodies to VEGFR-2. Confluent BAE cell monolayers on
three-dimensional collagen gels (control) were treated for 4 days with VEGF-A (50 ng/ml) or VEGFR-CNC (50 ng/ml) alone or in combination with a
neutralizing anti-human VEGFR-2 monoclonal antibody (IMC-1C11, 20 g/ml) or an isotype control (IMC-C225, 20 g/ml). Cell cord formation within the
collagen gel was viewed by phase-contrast microscopy. Coaddition of the neutralizing anti-VEGFR-2 antibody completely inhibited VEGF-A-induced
invasion and partially inhibited invasion induced by VEGF-CNC. Cells treated with IMC-1C11 alone showed no signs of cytotoxicity. No invasion occurred
in untreated cultures. Bar  100 m.
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20 g/ml, respectively (Figs. 7 and 8C), whereas the control
isotope antibody for IMC-1C11, namely IMC-C225, had no
effect (Figs. 7 and 8C). IMC-1C11 also partially inhibited
VEGF-C152-induced BAE cell invasion by 61.5% at 20
g/ml (Fig. 8D). No overt cytotoxicity was observed in any
antibody-treated cultures (Fig. 7 and data not shown).
Discussion
Members of the VEGF family of cytokines are the prin-
cipal inducers of angiogenesis and lymphangiogenesis iden-
tified to date. VEGFs -C and -D are unique among members
of this family in that the mature ligand is derived from the
precursor protein by cell-associated proteolytic processing
following secretion. Unprocessed ligand binds only to
VEGFR-3. Removal of the N- and C-terminal extensions
increases VEGF-C and -D’s affinity for VEGFR-3 and also
allows these molecules to bind to VEGFR-2. In the present
studies, we have used bovine endothelial cells whose
VEGFR profile has previously been determined [12,14], to
assess which of the VEGFRs is responsible for mediating
the in vitro biological activities of proteolytically processed
VEGF-CNC, and have compared this to signaling induced
by VEGF-A.
Using native and mutant forms of members of the VEGF
family as well as VEGFR antagonists, we demonstrate that
VEGF-CNC-induced endothelial cell invasion, capillary-
like tube formation, as well as PA and PAI-1 expression are
all mediated by VEGFR-2. Our findings with VEGF-A are
in accord with previous studies indicating that VEGFR-2 is
necessary and sufficient for endothelial cell proliferation,
migration, anti-apoptotic activity, gene expression, vascular
permeability, and angiogenesis [17,18,35,36]. Furthermore,
VEGFR-2 activation in endothelial cells has been impli-
cated in VEGF-A-mediated induction of COX-2, eNOS,
tissue factor [37–39], PAF synthesis [40], disruption of gap
junction-mediated communication [41], and intracellular
calcium mobilization [42].
We found that VEGF-CNC, a ligand for VEGFRs -2
and -3, mediated the same angiogenic activities as VEGF-A
through VEGFR-2 in BAE cells. VEGF-CNC is as potent
as VEGF-A in vivo in promoting angiogenesis, permeabil-
ity, endothelial cell proliferation, migration, and cell shape
changes in vitro [9–11]. On the other hand, tissue-specific
overexpression or adenoviral gene transfer of VEGF-C
or VEGF-C156 only induced lymphangiogenesis, and
VEGFR-3 was necessary for this process [4,5,43,44]. These
findings imply that the context in which VEGF-C is ex-
pressed is critical in determining an angiogenic vs lym-
phangiogenic response. Lymphatic endothelial cells express
VEGFR-2 and VEGFR-3 [45], and our data demonstrate a
role for VEGR-2 in VEGF-CNC-induced endothelial cell
function.
Our studies also demonstrate that the specificity of
VEGF-C-cys3ser mutants for VEGFRs is altered when
working across species barriers. Thus, human VEGF-C156,
which induces phosphorylation of human VEGFR-3 but not
VEGFR-2 [21], failed to induce phosphorylation of
VEGFR-3 in our system. In contrast, rat VEGF-C152, which
induces phosphorylation of VEGFR-3 in rodents [20], in-
duced phosphorylation of VEGFR’s -2 and -3 in bovine
endothelial cells. Rat VEGF-C152 also induced BAE cell
invasion, which could be partially inhibited by blocking
antibodies to VEGFR-2. These data have revealed species-
specific ligand-receptor interactions, and reinforce the im-
portance of VEGFR-2 in the induction of angiogenesis in
our system.
Although VEGF-A-induced invasion could be com-
pletely inhibited by blocking its binding to VEGFR-2,
VEGF-CNC- and VEGF-C152-induced invasion was only
partially blocked. Furthermore, coaddition of VEGF-A and
VEGF-CNC induces a synergistic in vitro angiogenic re-
sponse [12,46]. Taken together, these data suggest that the
binding sites for VEGFs -A and -C on VEGFR-2 may not
completely overlap [47,48]. This raises the question as to
the degree of similarity in the signal transduction pathways
which modify gene expression following VEGF-A or
VEGF-C-induced VEGFR-2 phosphorylation.
Capillary morphogenesis is a complex process, which is
partially dependent on extracellular proteolytic activity. The
PA-plasmin and matrix metalloproteinase systems have
been most extensively studied in this regard [49]. We have
previously reported that VEGF-A and VEGF-CNC induce
components of the PA-plasmin system in bovine endothelial
cells [12]. Here we show that this effect is mediated by
VEGFR-2. We have also reported that VEGF-B186, a ligand
for VEGFR-1, induces uPA and PAI-1 in BME and BAE
cells [23]. However, contrary to what we have previously
published, we have not been able to repeat these findings
consistently, and have found that VEGF-B167- or VEGF-
B186-induced PA and PAI-1 expression can be suppressed
by the addition to the cells of polymyxin-B, an inhibitor of
LPS [50]. We therefore conclude that VEGFR-2, but not
VEGFR-1, mediates induction of components of the PA-
plasmin system in our cells.
Our results are in agreement with recent reports which
indicate that VEGFR-2 is the main receptor for VEGF-A
and VEGF-C-induced angiogenesis in vitro [46,51]. How-
ever, in our system, VEGF-CNC and VEGF-C152 induced
angiogenesis in BAE but not BME cells, despite the fact that
both cell types express VEGFR-2 and that VEGF-CNC is
able to phosphorylate VEGFR-2 in both cell types. VEGF-C
does not bind neuropilin-1 [52,53] but does bind neuropi-
lin-2 [54]. This raises the possibility that a coreceptor such
as neuropilin-2 is required for invasion in BAE cells [55]. A
role for neuropilins in our model system is currently under
investigation.
In conclusion, we have shown that a number of biolog-
ical processes relevant to angiogenesis (endothelial cell in-
vasion and tube formation, regulation of PA gene expres-
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sion) are induced by members of the VEGF family (VEGF-
CNC and -A) which signal through VEGFR-2.
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Factor-Induced Angiogenesis in Vitro
Jean-Christophe Tille and Michael S. Pepper1The role of soluble factors (including angiogenic cy-
tokines) and extracellular matrix components in the
regulation of angiogenesis is clearly established. How-
ever, the interrelationship between these factors and
perivascular mesenchymal cells is not well under-
stood. Here we have used a three-dimensional collagen
gel coculture system to assess the effect of mesenchy-
mal C3H10T1/2 cells on vascular endothelial growth
factor-A (VEGF-A)- and fibroblast growth factor-2
(FGF-2)-induced angiogenesis in vitro. We found that
coculture markedly potentiated the angiogenic activ-
ity of VEGF-A, irrespective of whether or not direct
cell-to-cell contact occurred. In contrast, under condi-
tions in which cell-to-cell contact was possible, FGF-2-
induced angiogenesis was inhibited by cocultured
10T1/2 cells; this effect was not seen when cell-to-cell
contact was prevented. Attempts to identify the mole-
cules responsible for this effect allowed us to exclude
FGF-2, transforming growth factor1, platelet derived
growth factor-BB, angiopoietin-1, and NO as possible
mediators of the potentiating effect of coculture on
VEGF-A-induced invasion. In the living organism, an-
giogenesis occurs in a three-dimensional microenvi-
ronment. Contrary to the inhibitory effect of 10T1/2
cells previously reported by others in two-dimensional
cultures, our data demonstrate that the paracrine in-
teraction between endothelial and mesenchymal cells
potentiates angiogenesis in vitro and that this is cyto-
kine-specific, i.e., it occurs with VEGF-A but not with
FGF-2. © 2002 Elsevier Science (USA)
Key Words: angiogenesis; VEGF-A; FGF-2; endothe-
lium; mesenchyme; collagen.
INTRODUCTION
Angiogenesis, the formation of new capillary blood
vessels, occurs in a wide range of developmental, phys-
iological, and pathological settings. The process begins
with a phase of activation which includes local disas-
1 To whom correspondence and reprint requests should be ad-
dressed at Department of Morphology, University Medical Center, 1
rue Michel Servet, 1211 Geneva 4, Switzerland. Fax: 0041-22-702-
5338. E-mail: michael.pepper@medecine.unige.ch.
179sociation of pericytes or smooth muscle cells (perivas-
cular cells) from the existing vessel wall. This removes
growth inhibitory signals and enables endothelial cells
to respond to incoming positive angiogenic signals.
This results in increased vascular permeability and
extravascular fibrin deposition, basement membrane
degradation, endothelial and perivascular cell migra-
tion, and lumen formation. These events are followed
by the phase of resolution that includes inhibition of
endothelial and perivascular cell proliferation and mi-
gration, basement membrane reconstitution, and junc-
tional complex maturation. Vessel wall maturation is
completed by recruitment of perivascular cells, follow-
ing which endothelial cells enter a prolonged phase of
quiescence [1, 2]. Many cytokines are implicated in the
regulation of these events including vascular endothe-
lial growth factor-A (VEGF-A), fibroblast growth fac-
tor-2 (FGF-2), platelet derived growth factor-BB
(PDGF-BB), transforming growth factor 1 (TGF1)
and the angiopoietins (Ang) [reviewed in 3].
VEGF-A is an endothelial-cell-specific mitogen
which acts through two tyrosine kinase receptors,
VEGFR-1/Flt and VEGFR-2/Flk-1/KDR, whose expres-
sion is restricted to endothelial cells, monocytes, and
hematopoietic precursors. Disruption of either the
VEGFR-1 or the VEGFR-2 genes results in lethal em-
bryonic vascular and/or hematopoietic abnormalities.
Similar defects have been described in mice lacking a
single copy of the VEGF-A gene, which indicates a
crucial dose-dependent requirement for VEGF-A dur-
ing early development [reviewed by 4]. Furthermore,
VEGF-A acts as a survival factor for newly formed
retinal vessels prior to investment by perivascular cells
[5, 6].
FGF-2 is a potent angiogenic cytokine that to date
has been shown to be important in tumor rather than
developmental angiogenesis [reviewed in 7]. Interest-
ingly, FGF-2 interacts with VEGF-A in a synergistic
manner both in vitro and in vivo [8, 9]. Furthermore,
endogenous endothelial cell FGF-2 has been shown to
be an important coeffector of VEGF-A-induced angio-
genesis in vitro [10].Department of Morphology, University M ical Center, 1211 Geneva 4, SwitzerlandedPDGF-BB is required for vascular smooth muscle
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cell and pericyte proliferation and migration [11]. Mice
deficient in PDGF-B or PDGF-R die late in gestation
from hemorrhage, which in turn is the result of micro-
vascular pericyte loss with subsequent microaneurysm
formation and capillary rupture [12, 13].
Genetic studies have revealed that members of the
angiopoietin family play an important role in endothe-
lial–perivascular cell-to-cell interactions. Overexpres-
sion of angiopoietin-2 (Ang-2), as well as inactivation of
angiopoietin-1 (Ang-1) or Tie2 (the receptor for Ang-1
and Ang-2), all led to a similar phenotype comprising
immature dilated vessels with local hemorrhages [14].
In vivo, migrating endothelial sprouts are frequently
accompanied by migrating nonendothelial cells includ-
ing pericytes, smooth muscle cells, or fibroblasts [15,
16]. Modulation of endothelial differentiation by
perivascular cells appears to require direct cell–cell
contact. Microvascular pericytes have been reported to
inhibit the proliferation and migration of endothelial
cells in vitro [17, 18]. TGF1 was identified as the
mediator responsible for this effect. Both the inhibitory
effect and the conversion of latent to active TGF1
appeared to require cell–cell contact between endothe-
lial cells and pericytes or smooth muscle cells [19, 20].
Previous studies have shown that the pluripotent
mouse mesenchymal C3H10T1/2 (referred to hereafter
as 10T1/2) cell line can be induced to differentiate into
myoblasts, adipocytes, or chondrocytes [21]. A two-
dimensional in vitro model of endothelial and 10T1/2
cell coculture has been described in which endogenous
TGF1 induced 10T1/2 cells to express smooth muscle
-actin, a differentiation marker for the smooth muscle
cell phenotype. Further studies in vivo demonstrated
that these cells could be incorporated into the media of
developing blood vessels [22].
The aim of the present study was to determine the
effect of two major angiogenic cytokines, namely
VEGF-A and FGF-2, on cocultures of endothelial and
10T1/2 mesenchymal cells in a three-dimensional col-
lagen gel assay of endothelial cell invasion and capil-
lary morphogenesis.
MATERIALS AND METHODS
Reagents. Recombinant human FGF-2 was kindly provided by
Dr. P. Sarmientos (Farmitalia Carlo Erba, Milan, Italy). Recombi-
nant human VEGF-A165 was purchased from PeproTech, Inc. (Rocky
Hill, NJ). Recombinant human PDGF-BB was kindly provided by Dr.
G. Gabbiani (Dept. of Pathology, University Medical Center, Geneva,
Switzerland). Human TGF1 was purchased from R&D Systems
Europe (Abingdon, Oxon, UK). PDGF-BB tyrosine kinase inhibitor
(CGP53176) was provided by Dr. J. Wood (Novartis Pharma AG,
Basel, Switzerland), VFM17 and VFM23A were kindly provided by
Dr. N. Ferrara (Genentech, Inc., South San Francisco, CA), and
VEGFR-2 tyrosine kinase inhibitor (SU5416) was provided by Sugen
(South San Francisco, CA). Recombinant human Tie2-Fc was pro-
vided by G. Yancopoulos (Regeneron, Tarrytown, NY) and has pre-
viously been shown to bind human and mouse angiopoietins [23].
L-NAME was purchased from Lc Laboratoire (Switzerland). BB-94
was provided by British Biotech (Oxford, UK). Antibodies used were
as follows: monoclonal anti-bovine FGF-2 antibody (No. 05-117, Up-
state Biotechnology, Inc., Lake Placid, NY), monoclonal anti-rh-
VEGF-A antibody (MAB293, R&D Systems, Minneapolis, MN),
monoclonal anti-mouse VEGF-A antibody (AF-493-NA, R&D Sys-
tems), polyclonal anti-human TGF1 antibody (AB-101-NA, R&D
Systems), polyclonal anti-human PDGF-BB antibody (AB-220-NA,
R&D Systems), monoclonal anti-keyhole limpet hemocyanin (KLH)
antibody (03210D, Pharmingen Europe).
Cell culture. Bovine adrenal cortex-derived microvascular endo-
thelial (BME) cells provided by Drs. M. B. Furie and S. C. Silverstein
(Columbia University, NY [24]) were grown in minimal essential
medium,  modification (-MEM) (Invitrogen AG, Basel, Switzer-
land), supplemented with heat-inactivated donor calf serum (DCS,
Invitrogen AG), penicillin (110 U/ml), and streptomycin (110 g/ml).
Bovine aortic endothelial (BAE) cells were cultured in low-glucose
Dulbecco’s modified minimal essential medium (DMEM, Invitrogen
AG) supplemented with 10% DCS and antibiotics [25]. C3H/10T1/2
(10T1/2) cells (CCL-226, ATCC, Manassas, VA) were cultured in
high-glucose DMEM supplemented with 10% DCS and antibiotics.
In vitro angiogenesis assay. The in vitro angiogenesis assay was
performed as described [26]. BME cells were seeded onto 500-l
three-dimensional rat Type I collagen gels in 16-mm tissue culture
wells (Nunc, Roskilde, Denmark) at 2  105 cells/ml in 500 l
-MEM with 2% DCS. For coculture, 10T1/2 cells were seeded in
suspension in the collagen gel at 1  105 cells/ml. When endothelial
cells reached confluence (3 days), cells were treated with cytokines
and/or antagonists. Antagonists were added to the cells 2 h before
cytokines on the first day of treatment.
For the collagen gel “sandwich” assay [27], BME cells were seeded
at 1  105 cells/ml onto a 400-l collagen gel. One hour later,
unattached cells were removed and 400 l of collagen was added
above the attached cells, effectively sandwiching them between two
layers of collagen. For coculture experiments, 10T1/2 cells were
seeded in suspension in the collagen gel at 1  105 cells/ml. Cells
were treated with cytokines after polymerization of the second col-
lagen layer.
For insert models, BME cells were seeded into the upper chamber
of transwells (Falcon 3095, Becton–Dickinson, Franklin Lakes, NJ)
at 2  105 cells/ml onto a 300-l collagen gel, and 10T1/2 cells were
seeded in suspension into the lower compartment at 5  104 cells in
200 l of collagen. In the reverse experiment, BME cells were seeded
into the lower compartment and 10T1/2 cell into the upper chamber
of the transwell.
Cultures were photographed under phase contrast microscopy us-
ing a Nikon Diaphot TMD inverted photomicroscope (Nikon, Tokyo,
Japan). Quantitation was performed as described [9]. Results are
shown as the mean additive sprout length SEM (in m) for at least
three experiments per condition. Mean values were compared using
Student’s unpaired t test, and a significant P value was taken as
0.05.
Conditioned media (CM) were obtained as follows. BME cells (6 
105 cell/ml), 10T1/2 cells (6  105 cell/ml), or cocultures of BME and
10T1/2 cells (at 3  105 cell/ml each) were grown on 1.5% gelatin-
coated plates in 50% v/v of the respective medium for each cell line
plus 2% DCS. At confluence, medium was renewed and cells were
incubated with VEGF-A (100 ng/ml) or with complete medium for 4
days. Conditioned media were filtered through a 0.2-m filter to
remove cells debris and were stored at 20°C until use.
RT-PCR. 10T1/2 cells were seeded in suspension in collagen gels
at 1  106 cells/ml. For RT-PCR, 2 g of total cellular RNA was
purified using Trizol reagent (Gibco BRL) and reverse-transcribed
using random primers (Promega) and Superscript II (Gibco) as rec-
ommended by the manufacturer. For each RT product, one-tenth of
the final reaction volume was amplified by PCR using oligonucleo-
tides for mouse VEGF-A, VEGFR-1, and VEGFR-2 [28], and degen-
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erate oligonucleotides for Ang-1, Ang-2, Tie-1, and Tie-2 [29]. PCR
products were electrophoresed in agarose gels containing ethidium
bromide.
Zymography, reverse zymography, and gelatin zymography. BME
or 10T1/2 cells were grown to confluence in 35-mm dishes in their
respective medium  5% DCS. At confluence, medium was removed
and the cells were washed twice with phosphate-buffered saline and
then incubated with serum-free medium containing 200 Kallikrein
inhibitory units/ml Trasylol (Bayer-Pharma AG, Zurich, Switzer-
land), cytokines, or conditioned medium for 15 h. Supernatants and
cells lysates were harvested and analyzed by zymography and re-
verse zymography as previously described [30]. For gelatin zymog-
raphy, 45 l of supernatant was electrophoresed under nondenatur-
ing conditions in 7.5% SDS/polyacrylamide gel copolymerized with 1
mg/ml of gelatin (Merck, Dietikon, Switzerland). The gel was washed
twice for 15 min in 2.5% Triton X-100, incubated in 50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 10 mM CaCl2, and 0.02% NaN3 for 16 h at
37°C and then stained for 1 h in 30% methanol, 10% acetic acid with
0.5% Coomassie blue, and destained for 15 min in 30% methanol,
10% acetic acid. Zones of proteolytic activity were visualized as clear
bands against a dark blue background. The conditioned media from
MCF-7 and U973 cell lines, which are known to secrete MMP-2 and
MMP-9 respectively, were used as positive controls.
RESULTS AND DISCUSSION
10T1/2 Cells Potentiate VEGF-A-Induced
Angiogenesis in Vitro
Our initial objective was to determine whether plu-
ripotent 10T1/2 mesenchymal cells could modulate cy-
tokine-induced angiogenesis in a three-dimensional
collagen gel coculture assay [31]. BME cells were
seeded onto the surface of collagen gels which either
did or did not contain 10T1/2 cells growing in suspen-
sion. At confluence, BME cells formed a monolayer on
the gel surface, and the presence of 10T1/2 cells within
the collagen gel did not induce BME cell invasion, as
reported previously [31] (Fig. 1). Confluent monolayers
of BME cells were then induced to invade the collagen
gels by the addition of VEGF-A or FGF-2 (Fig. 1).
Cocultures treated with VEGF-A showed a marked
increase in tube formation over and above that induced
by VEGF-A alone (Figs. 1 and 2). On the other hand,
FIG. 1. 10T1/2 cells potentiate VEGF-A-induced in vitro angiogenesis. Confluent monolayers of BME cells on three-dimensional collagen
gels or in coculture with 10T1/2 cells in suspension in collagen gels were treated with VEGF-A (100 ng/ml) or FGF-2 (10 ng/ml) for 4 days.
The resulting capillary-like tubular structures were viewed by phase contrast microscopy. In these experiments, a cell-free collagen gel was
interposed between the endothelial cell monolayer and the 10T1/2 cells cultured in suspension.
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coculture strongly inhibited invasion induced by FGF-2
when compared to BME cells treated with FGF-2 alone
(Fig. 2A). To determine whether the potentiating effect
of 10T1/2 cells on VEGF-A-induced invasion was re-
stricted to BME cells, confluent BAE cell monolayers
were stimulated with VEGF-A or FGF-2 in the pres-
ence or absence of cocultured 10T1/2 cells. We observed
a similar modulation of cytokine-induced invasion by
10T1/2 cells in both cell lines (Fig. 2A). 10T1/2 cells on
their own induced a limited degree of invasion in BAE
cells (Fig. 2A).
In the next series of experiments, a collagen layer
was added between 10T1/2 and BME cells in order to
prevent direct cell–cell contact. This was done to as-
sess the possible role of contact in the potentiation of
VEGF-A activity or the inhibition of FGF-2 activity.
Under these conditions, VEGF-A-induced invasion was
still enhanced in coculture, albeit to a slightly lesser
extent than that observed where cell–cell contact was
potentially possible (Fig. 2A). The addition of a cell-free
collagen layer between endothelial and 10T1/2 cells
restored the full capacity of FGF-2 to induce invasion
in both endothelial cell lines (Figs. 1 and 2A). These
results indicate that direct contact between endothelial
cells and 10T1/2 cells may be required for the inhibi-
tory effect on FGF-2-induced invasion but not for the
potentiation of VEGF-A-induced invasion. The slight
decrease in VEGF-A-induced invasion when a collagen
layer was added suggested that a diffusable factor me-
diates the potentiation of VEGF-A-induced invasion.
In a checkerboard-type experiment, we next as-
sessed whether potentiation was dependent on
VEGF-A concentration and/or 10T1/2 cell density. We
found that BME cell invasion was indeed dependent on
both VEGF-A concentration and 10T1/2 cell density
(Fig. 2B).
The results obtained above suggested that a diffus-
able factor mediates 10T1/2 cell potentiation of VEGF-
A-induced angiogenesis. In order to explore this hy-
pothesis, CM from VEGF-A-stimulated BME cells,
VEGF-A-stimulated 10T1/2 cells, or VEGF-A-treated
cocultures were tested on BME cells alone in the col-
lagen gel invasion assay. All CMs induced BME cell
invasion but to a lesser extent than VEGF-A alone
(Fig. 3A). A neutralizing anti-rhVEGF-A monoclonal
antibody blocked CM-induced angiogenesis in all cases,
indicating that invasion resulted from exogenously
added VEGF-A which remained in the CM (Fig. 3A).
A transwell insert system was used in which 10T1/2
cells were seeded in suspension in a collagen gel into
the upper compartment and BME cells suspended in a
collagen gel into the lower compartment and vice
versa. Under these conditions, VEGF-A-induced BME
cell invasion in either compartment was identical to
that induced in the absence of coculture, i.e., markedly
less than that induced by VEGF-A in the coculture
experiments described above (Fig. 3A). These findings
indicate that the 10T1/2 cell-derived potentiating fac-
tor is lost during long-range diffusion, suggesting that
it might be relatively unstable. This is in accord with
the inability of conditioned medium to reproduce the
effect of coculture.
To further assess the presence of a potential media-
tor in conditioned medium, MMP-2, uPA, tPA, and
PAI-1 activities were measured by zymography or re-
verse zymography (for PAI-1). When conditioned media
were added to BME cells, all induced a small increase
FIG. 2. Quantitative assessment of the effect of 10T1/2 cells on
cytokine-induced in vitro angiogenesis. (A) Confluent monolayers of
BME and BAE cells on three-dimensional collagen gels were cul-
tured alone (endothelial cells), in coculture allowing direct contact
(Co-cult. contact), or with a collagen-free layer between endothelial
cells and 10T1/2 cells (Co-cult. contact-free). Cultures were treated
with VEGF-A (100 ng/ml) or FGF-2 (10 ng/ml for BME and 3 ng/ml
for BAE cells). After 4 days, invasion, expressed as total additive
sprout length (in m  SEM), was quantitated. Results are from at
least three separate experiments per condition. *P  0.001, when
compared to invasion induced by 10T1/2, VEGF-A, or FGF-2 in
coculture versus endothelial cells alone (Student’s unpaired t test).
(B) Confluent monolayers of BME cells on three-dimensional colla-
gen gels or in coculture with the indicated concentrations of 10T1/2
cells in suspension in collagen gels were treated with the indicated
concentration of VEGF-A. After 4 days, invasion, expressed as total
additive sprout length (in m  SEM), was quantitated. Results are
from at least three separate experiments per condition.
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FIG. 3. Quantitative assessment of conditioned medium on angiogenesis in vitro, PA, and MMP-2 activity. (A) Confluent monolayers of
BME cells on three-dimensional collagen gels were treated with VEGF-A (100 ng/ml), CM (50%, v/v) from 10T1/2 cells (CM T101/2(V)), BME
cells (CM BME(V)), and coculture (CM Co-cult. (V)) treated with VEGF-A (100 ng/ml). Where indicated, an anti-human VEGF-A monoclonal
antibody (500 ng/ml) was added. Inset model: BME cells on three-dimensional collagen gels in the upper chamber and 10T1/2 cells in
suspension in collagen gel in the lower part of the inset. After 4 days, invasion, expressed as total additive sprout length (in m SEM), was
quantitated. Results are from at least three separate experiments per condition. (B) Confluent BME cell monolayers were incubated with
medium containing 1% serum, VEGF-A (100 ng/ml), CM (50%, v/v) from 10T1/2 cells (CM 10T1/2), BME cells (CM BME), coculture (CM
Co-cult.) with or without VEGF-A (100 ng/ml) (V) for 15 h. At the end of the incubation, BME cell culture supernatants (SN) were subjected
to zymography. Three experiments were performed and similar results were obtained. (C) Confluent BME cell monolayers were incubated
as described in (B) for 15 h. At the end of the incubation, BME cell culture supernatants (SN) were subject to gelatin zymography. Latent
MMP-2 (lat MMP-2); activated MMP-2 (act MMP-2). Three experiments were performed and similar results were obtained. MMP-2 and
MMP-9 are standards as described under Materials and Methods.
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in activated MMP-2, uPA, and PAI-1 (Fig. 3B and data
not shown). When conditioned media prepared in the
presence of VEGF-A were added to BME cells, uPA was
induced in a manner similar to that seen with VEGF-A
alone; no increment was seen in the activation of
MMP-2 over and above that seen in the absence of
VEGF-A (Fig. 3B). Interestingly, however, the induc-
tion of tPA by VEGF-A was inhibited by all conditioned
media. These findings point to the presence of a factor
in conditioned medium capable of inducing an increase
in uPA, PAI-1, and activated MMP-2 and a decrease in
tPA. However, coaddition of VEGF-A to cocultures
prior to collecting the conditioned medium did not in-
crease uPA or PAI-1 or activated MMP-2 over and
above that seen with conditioned medium or VEGF-A
alone.
10T1/2 Cell-Induced Potentiation of VEGF-A-Induced
Angiogenesis Is Mediated through BME Cell
VEGFR-2
As shown above, 10T1/2 cells potentiate VEGF-A-
induced angiogenesis in a cell-density-dependent man-
ner. VEGF-A binds VEGFR-1 and VEGFR-2, both of
which are expressed by BME and BAE cells [32]. How-
ever, the VEGFR expression profile of 10T1/2 cells was
not known. This prompted us to determine whether
10T1/2 cells express VEGF-A, VEGFR-1, and
VEGFR-2. Total cellular RNA from 10T1/2 cells grown
in suspension in collagen gels for 4 days was subjected
to RT-PCR analysis. We found that 10T1/2 cells ex-
press the 164- and 120-amino-acid isoforms of
VEGF-A, as well as VEGFR-1 but not VEGFR-2 (Fig.
4A). No bands were observed if RT was omitted, ruling
out the possibility that the bands were derived from
contaminating genomic DNA (Fig. 4A). This finding
left open the possibility that the potentiation of VEGF-
A-induced angiogenesis might be mediated by 10T1/2
cell VEGFR-1.
In order to assess the specific roles of VEGFRs-1 and
-2 in cocultures, we used ligands which display selec-
tivity for either receptor. The VEGF-A mutants VFM17
and VFM23A were obtained by alanine-scanning mu-
tagenesis and specifically bind VEGFR-1 and -2, re-
spectively [33, 34]. Like VEGF-A, VFM23A induced
BME cell collagen gel invasion both in coculture and
when BME cells were cultured alone (Fig. 4B and Tille
et al., submitted). VFM17, on the other hand, lacked
invasion-inducing activity (Fig. 4B and Tille et al.,
submitted). These findings argued against a role for
VEGFR-1, and thereby VEGF-A stimulation of 10T1/2
cells, in the potentiating effect. This was supported by
the observation that VEGF-A had no effect on 10T1/2
cell uPA, tPA, and PAI-1 activity as assessed by zy-
mography or reverse zymography (Fig. 6B).
Next, we examined the effect of SU5416, an inhibitor
of VEGFR-2 tyrosine kinase phosphorylation [35, 36],
in our coculture system. We observed complete inhibi-
tion of in vitro angiogenesis in coculture (Fig. 4B).
These results clearly indicate that signaling via BME
cell VEGFR-2 is crucial for the potentiation of VEGF-
A-induced angiogenic activity in coculture.
Based on these results, we hypothesized that exog-
enously added VEGF-A binds VEGFR-2 on BME cells.
This in turn might stimulate the secretion of a diffus-
ible factor from BME cells that interacts with 10T1/2
cells and induces the release of a paracrine inducer of
BME cell invasion.
FIG. 4. Coculture-induced potentiation of VEGF-A-induced inva-
sion is mediated via VEGF-R2. (A) Two micrograms of total RNA
from adult mouse lung (control for VEGF-A, VEGF-R1 and VEGF-
R2) or 10T1/2 cells in suspension in collagen gels was reverse-tran-
scribed. One-twentieth of the volume of the RT products, or an
equivalent volume of H2O, was subjected to PCR in the presence of
specific mouse oligonucleotides for VEGF-A, VEGF-R1, and VEGF-
R2. Where indicated, RT was omitted. (B) Confluent monolayers of
BME cells on three-dimentional collagen gels in the presence or
absence of cocultured cells were treated with VEGF-A (100 ng/ml),
VFM17 (100 ng/ml), VFM23A (100 ng/ml), or SU5416 (10 M). After
4 days, invasion, expressed as total additive sprout length (in m 
SEM), was quantitated. Results are from at least three separate
experiments per condition.
184 TILLE AND PEPPER
Effect of Various Inhibitors on 10T1/2-Induced
Potentiation of VEGF-A-Induced Angiogenesis
VEGF-A derived from vascular smooth muscle cells or
fibroblasts has been shown to induce endothelial cells to
invade collagen gels [37, 38]. Our findings from RT-PCR
analysis indicated that 10T1/2 cells express VEGF-A164
and VEGF-A120 but not VEGF-A189 isoforms (Fig. 4A).
This prompted us to investigate whether mouse VEGF-A
derived from 10T1/2 cells could potentiate VEGF-A-in-
duced angiogenesis in coculture. Confluent monolayers of
BME cells on a three-dimensional collagen gels contain-
ing 10T1/2 cells in suspension were treated with recom-
binant human VEGF-A and a neutralizing anti-mouse
VEGF-A monoclonal antibody added to the collagen gel.
Invasion was slightly decreased by the anti-mouse
VEGF-A antibody but remained increased above that
seen with VEGF-A-treated BME cells alone (Fig. 5A).
The anti-mouse VEGF-A antibody did not affect invasion
induced by rhVEGF-A in the absence of coculture (data
not shown). These results indicate that VEGF-A secreted
by 10T1/2 cells is not sufficient to induce BME cell inva-
sion or to potentiate the activity of exogenously added
rhVEGF-A, but participates to a minor extent in a para-
crine manner in in vitro angiogenesis in coculture.
FGF-2
We have previously reported that coaddition of
VEGF-A and FGF-2 induces a synergistic invasive re-
sponse in BME and BAE cells [8, 9]. Furthermore,
FGF-2 derived from fibroblasts has previously been
shown to stimulate HUVEC invasion in collagen gels
[37]. We reasoned that FGF-2 could act in a similar
manner in our model, but that it might be present at a
concentration which is insufficient to induce BME cell
invasion on its own. To assess this possibility, we
added a neutralizing anti-bovine FGF-2 antibody,
which cross-reacts with mouse FGF-2, to cocultures or
BME cell cultures alone, stimulated in both cases with
VEGF-A. In cultures with BME cells alone, complete
inhibition of collagen gel invasion was observed (Fig.
5B). In contrast, in cocultures, inhibition was only 60%
(Fig. 5B); an irrelevant anti-KLH antibody added at
the same concentration had no effect (Fig. 5B). We
have previously reported that VEGF-A-induced BME
cell collagen gel invasion is dependent on endogenous
FGF-2 [10]. We suggest, therefore, that the remaining
invasion observed in coculture is probably due to the
action of cytokines secreted from 10T1/2 cells which act
on BME cells in a paracrine manner.
The absence of FGF-2 from conditioned medium de-
rived from BME or 10T1/2 cells alone, or from cocul-
tures, was demonstrated as follows. Exogenously
added FGF-2 induced uPA in 10T1/2 cells, as deter-
mined by zymography (Fig. 6A). However, none of the
conditioned media, collected in the absence or presence
of VEGF-A, altered uPA expression in 10T1/2 cells
(Fig. 6B).
TGF1
Exogenously added TGF1 has a biphasic effect on
VEGF-A-induced BME cell invasion [39]. We therefore
FIG. 5. Effect of anti-cytokine antibodies on endothelial cell in-
vasion in coculture. (A) Confluent monolayers of BME cells on three-
dimensional collagen gels were treated with VEGF-A (100 ng/ml).
Cocultures were treated with VEGF-A (100 ng/ml) and a neutraliz-
ing anti-mouse VEGF-A monoclonal antibody (5 g/ml), a neutraliz-
ing anti-TGF1 polyclonal antibody (40 g/ml), a neutralizing anti-
PDGF-BB polyclonal antibody (10 g/ml), a PDGF-BB receptor
tyrosine kinase inhibitor (CGP 53176 at 10 M), L-NAME (200 M),
or BB94 (5 M). After 4 days, invasion, expressed as total additive
sprout length (in m  SEM), was quantitated. Results are from at
least three separate experiments per condition. **P  0.005, *P 
0.001, when compared to invasion induced by VEGF-A in coculture
(Student’s unpaired t test). (B) Confluent monolayers of BME cells on
three-dimensional collagen gels in the presence or absence of cocul-
tured cells were treated with VEGF-A (30 ng/ml) and a neutralizing
monoclonal anti-bovine FGF-2 antibody (10 g/ml) or an isotype
matched control antibody (anti-KLH antibody at 10 g/ml). After 4
days, invasion, expressed as total additive sprout length (in m 
SEM), was quantitated. Results are from at least three separate
experiments per condition.
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asked whether coculture might activate TGF1 de-
rived from BME and/or 10T1/2 cells and whether this
in turn might potentiate VEGF-A-induced collagen gel
invasion. However, we found that the addition of neu-
tralizing anti-TGF1 antibodies had no effect on
VEGF-A-induced potentiation in coculture, demon-
strating that TGF1 is unlikely to be the mediator of
the potentiation observed (Fig. 5A).
The absence of activated TGF1 from BME cell or
coculture-derived conditioned medium was demon-
strated as follows. Exogenously-added TGF1 induced
PAI-1 activity in 10T1/2 cells in a dose-dependent man-
ner, as determined by reverse zymography (Fig. 6A and
data not shown), demonstrating that these cells have
the capacity to respond to TGF1. In contrast, induc-
tion of PAI-1 by conditioned medium from BME cells
alone or from cocultures (Fig. 6B) was unaffected by
neutralizing anti-TGF1 antibodies (data not shown).
PDGF-BB
PDGF-BB has previously been shown to be angio-
genic in vitro and in vivo and appears to act between
endothelial and perivascular cells in a paracrine man-
ner [40, 41]. 10T1/2 cells expressed PDGF-R mRNA
while endothelial cells express PDGF-BB mRNA [42].
PDGF-BB induces significant morphological alter-
ations in 10T1/2 cells (data not shown). We hypothe-
sized that the increase in angiogenesis in coculture
might result in part from PDGF-BB released from
VEGF-A-stimulated BME cells [43] which could bind to
PDGF-R on 10T1/2 cells. To explore this possibility,
BME cells on collagen gels in the presence or absence of
coculture were incubated with VEGF-A and a neutral-
izing anti-PDGF-BB antibody or a PDGF-R tyrosine
kinase inhibitor (GCP53176) [44]. Neither PDGF-BB
neutralization nor receptor tyrosine kinase inhibition
modified VEGF-A-induced angiogenesis in the pres-
ence (Fig. 5A) or the absence of coculture (data not
shown). Furthermore, when cocultures were incubated
with PDGF-BB (50 ng/ml) for 4 days, no invasion oc-
curred (data not shown). These findings exclude a role
for PDGF-BB in the potentiation of VEGF-A-induced
invasion by 10T1/2 cells.
Angiopoietins
It has previously been demonstrated that Ang-1 po-
tentiates VEGF-A induced angiogenesis using human
microvascular endothelial cells [45–47]. Using BME
and BAE cells, we have observed a similar phenome-
non (Fig. 7A and data not shown).
To determine whether Ang-1 might induce a similar
effect in our coculture system, we first examined the
expression of components of the angiopoietin system in
10T1/2 cells. We found that these cells express Ang-1
but not Ang-2; 10T1/2 cells also express Tie2 but not
Tie1 (Fig. 7B and data not shown). We next added
Tie2-Fc to the medium or to the collagen gels of VEGF-
A-treated BME cells cultured alone or in the presence
of 10T1/2 cells. We have observed that Tie2-Fc is a
potent inhibitor of the potentiating effect of Ang-1 on
VEGF-A-induced angiogenesis in our system (Fig. 7A).
Addition of Tie2-Fc (up to 20 g/ml) had no effect on
the potentiating effect of cocultured 10T1/2 cells on
VEGF-A-induced BME cell invasion in the presence or
absence of coculture (Fig. 7C).
As indicated above (Fig. 3B and data not shown),
conditioned medium increased BME cell uPA and
PAI-1 activity. We have observed that neither Ang-1
nor Ang-2 alters BME or BAE cell uPA, tPA, or PAI-1
FIG. 6. Effect of cytokines and conditioned medium on 10T1/2
cell PA activity. (A) Confluent 10T1/2 cell monolayers were incubated
with TGF1 (1 ng/ml), FGF-2 (3 ng/ml), or serum-free medium (con-
trol) for 15 h. At the end of the incubation, culture supernatants (SN)
and cell extracts (CE) were analyzed by reverse zymography and
zymography, respectively. Three experiments were performed and
similar results were obtained. (B) Confluent 10T1/2 cell monolayers
were incubated with serum-free medium, VEGF-A (100 ng/ml), CM
(50%, v/v) from 10T1/2 cells (CM 10T1/2), BME cells (CM BME), or
coculture (CM Co-cult.) with or without simultaneous treatment
with VEGF-A (100 ng/ml) (V) for 15 h. At the end of the incubation,
culture supernatants (SN) and cell extracts (CE) were subjected to
reverse zymography and zymography, respectively. Three experi-
ments were performed and similar results were obtained.
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activity (data not shown). The factor in coculture CM
which alters BME cell uPA and PAI-1 activity is there-
fore unlikely to be Ang-1.
Taken together, these data strongly suggest that the
factor which induces potentiation of VEGF-A-induced
invasion in coculture is not Ang-1.
Other Mediators
NO has previously been implicated in endothelial
cell migration [48, 49], is a mediator of cytokine-in-
duced angiogenesis in vitro and in vivo [50, 51], and is
released from VEGF-A-stimulated endothelial cells
FIG. 7. Ang-1 is not the mediator of the potentiation of VEGF-induced invasion by coculture with 10T1/2 cells. (A) Confluent monolayers
of BME cells on three-dimensional collagen gels were treated with VEGF-A (30 ng/ml) and angiopoietin-1 (Ang-1) at the indicated
concentrations (left) or with VEGF-A (V, 30 ng/ml), Ang-1 (500 ng/ml), or Tie2-Fc (5 g/ml) as indicated (right). After 4 days, invasion,
expressed as total additive sprout length (in m  SEM), was quantitated. Results are from at least three separate experiments per
condition. *P  0.02, **P  0.001, when compared to VEGF-A-treated BME cells (Student’s unpaired t test). (B) Two micrograms of total
RNA from adults mouse lung (control for Ang-1 and Ang-2) or 10T1/2 cells in suspension in collagen gels was reverse-transcribed.
One-twentieth of the volume of the RT products or an equivalent volume of H2O, was subjected to PCR in the presence of degenerate
oligonucleotides for Ang-1 and Ang-2. Where indicated, RT was omitted. (C) Confluent monolayers of BME cells on three-dimensional
collagen gels or in coculture with 10T1/2 cells were treated with VEGF-A (30 ng/ml) or VEGF-A and Tie2-Fc (5 g/ml) in the culture medium
or in the collagen gel (Tie2-Fc coll). After 4 days, invasion, expressed as total additive sprout length (in m SEM), was quantitated. Results
are from at least three separate experiments per condition.
187MESENCHYMAL CELLS POTENTIATE VEGF-INDUCED ANGIOGENESIS
[52–54]. We used an NO-synthase inhibitor NG-nitro-
L-arginine methyl ester (L-NAME) to test whether NO
might mediate the potentiation of VEGF-A-induced an-
giogenesis in coculture. BME cells on collagen gels
alone or in coculture were incubated with VEGF-A and
L-NAME. L-NAME had no effect on VEGF-A-induced
BME cell invasion in the presence or absence of cocul-
ture (Fig. 5A).
Matrix metalloproteinases (MMPs) play an impor-
tant role in endothelial cell pericellular matrix degra-
dation and angiogenesis [reviewed by 55], and produc-
tion of MMPs -1, -3, and -9 by smooth muscle cells is
enhanced by VEGF-A in an apparently VEGFR-1-de-
pendent manner [56]. To assess the role of MMPs in
our system, VEGF-A-stimulated cocultures were
treated with BB94, a broad spectrum MMP inhibitor
[57]. BB94 completely inhibited VEGF-A-induced BME
cell invasion in the presence or absence of coculture
(Fig. 5A), demonstrating the requirement for MMP
activity.
10T1/2 Cells Potentiate VEGF-A-Induced Tube-like
Capillary Morphogenesis and Endothelial Survival
in Vitro
The three-dimensional in vitro model used in the
studies described thus far recapitulates many ele-
ments of the activation phase of the angiogenic process,
including proliferation and migration/invasion. To fur-
ther explore the interaction between 10T1/2 and BME
cells, we have employed a second model of angiogenesis
which recapitulates the resolution phase of angiogen-
esis. In this model, endothelial cells at low density are
sandwiched between two layers of collagen. Sandwich-
ing has three effects: inhibition of proliferation, induc-
tion of capillary-like tube formation (Fig. 8A), and in-
duction of endothelial cell apoptosis [58]. When 10T1/2
cells were added in suspension at different concentra-
tions to both collagen layers, capillary-like morphogen-
esis and BME cell survival were decreased in a density-
dependent manner (data not shown). However,
network formation and survival were increased by ex-
ogenous VEGF-A, and this effect was enhance in cocul-
ture (Figs. 8A and 8B). In contrast, FGF-2 had no
significant effect on BME cell reorganization or sur-
vival, either in the presence or in the absence of cocul-
ture (Fig. 8B).
Conclusions and Summary
In this study, we report that VEGF-A-induced in
vitro angiogenesis in three-dimensional collagen gels is
potentiated by mesenchymal cells in coculture. 10T1/2
cells alone did not induce angiogenesis. Potentiation of
invasion was dependent on VEGF-A concentration and
10T1/2 cell density. This effect did not require endo-
thelial–mesenchymal cell–cell contact, as demon-
strated by the fact that the interposition of a cell-free
collagen gel between the two cell types did not abrogate
the effect. The effect was specific for VEGF-A and was
not observed with FGF-2. In cocultures which permit
cell–cell contact, FGF-2-induced invasion was de-
creased compared to cultures with endothelial cells
alone, while addition of an intermediate collagen layer
between the two cells types restored FGF-2-angiogenic
activity. The potentiating effect of coculture on VEGF-
A-induced invasion was dependent on VEGFR-2 sig-
naling. Since 10T1/2 cells do not express VEGFR-2, our
findings suggest that potentiation is mediated by the
release of a soluble factor(s) from VEGF-A-stimulated
BME cells. We have not been able to establish whether
this factor interacts in concert with a 10T1/2 cell-de-
rived factor on BME cells or whether the BME cell-
derived factor stimulates 10T1/2 cells in turn to release
another modulator. The low stability of this factor,
and/or the fact that exogenously-added VEGF-A is re-
quired to see the effect, has significantly hindered our
attempts to demonstrate its presence in conditioned
medium derived from BME cells, 10T1/2 cells, or the
two in coculture in two or three dimensions.
In our attempts to identify mediators of the potenti-
ation effect, we have considered a number of cytokines
and other mediators that have been implicated in the
regulation of angiogenesis. Studies on cocultures and
conditioned medium using a variety of inhibitors has
allowed us to exclude FGF-2, TGF1, PDGF-BB,
Ang-1, and NO as the major mediators of the potenti-
ating effect of VEGF-A on invasion in coculture. PIGF,
PD-ECGF, IL-8, PDGF-AA, HGF, EGF, and G-CSF
have no angiogenic effect in our model [31] and do not
potentiate the effect of VEGF-A (data not shown).
In summary, we have used a three-dimensional co-
culture system to assess the effect of mesenchymal
cells on cytokine-induced angiogenesis in vitro. Con-
trary to the inhibitory effect of 10T1/2 cells previously
reported by others [17, 18, 22], we found that when
endothelial cells are cocultured with 10T1/2 cells,
VEGF-A-induced angiogenesis is markedly potenti-
ated. This apparent discrepancy may be due to differ-
ences in the configuration of the assays in the different
studies; our study has used cells cultured in a three-
dimensional rather than a two-dimensional configura-
tion. In vivo, angiogenesis occurs in a three-dimen-
sional microenvironment. Although we have not been
able to identify the mechanism of potentiation, despite
considerable efforts on our behalf, our data demon-
strate the dual requirement for VEGF-A and the para-
crine interaction between endothelial and mesenchy-
mal cells in the induction of angiogenesis in vitro.
Mature blood vessels are characterized by endothelial
quiescence, which is mediated by inhibitory signals
from perivascular cells (pericytes and smooth muscle
cells) on endothelial cell proliferation. The absence of
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this inhibitory effect on VEGF-A-induced angiogenesis
in our system demonstrates that mesenchymal cells
alone are unable to mediate this effect. On the con-
trary, in their undifferentiated state, mesenchymal
cells potentiate angiogenesis. Our findings, together
with those published previously, suggest the existence
of a temporal sequence in which the transition from the
activation to the resolution phase of angiogenesis oc-
curs concomitantly with the differentiation of mesen-
chymal cells into pericytes and smooth muscle cells.
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Tufted angioma is a rare benign vascular lesion of unknown etiology
which mainly affects children under 5 years. It is characterized by
nodules or tufts of capillary-sized vessels in the dermis. Here we report
the second familial occurrence of tufted angioma, with a mode of
inheritance compatible with a monogenic autosomal dominant trait with
reduced penetrance. A preliminary investigation was performed to
exclude association between the predisposition and certain candidate
genes including KDR (kinase insert domain receptor), TEK (TEK
tyrosine kinase endothelial), ACVRL1 (activin receptor-like kinase 1),
ENG (endoglin) and FLT4 (fms-like tyrosine kinase 4). KDR, ENG and
FLT4 were all compatible with linkage, with haplotypes being shared
between three affected individuals and the one obligate carrier available
for testing. TEK and ACVRL1 could essentially be excluded. Finally, we
provide definitive evidence for the existence of both blood and lymphatic
vascular elements in the lesion.
Tufted angioma is a rare benign vascular lesion of
unknown etiology which predominately affects
children under 5 years of age, although it may
occur in adulthood (1, 2).Cases havebeen reported
to occur during pregnancy (in the mother), while
others may be congenital (3, 4). There is no signifi-
cant gender predilection. The lesions appear pre-
dominately on the neck, shoulders and trunk (1, 5),
although other localizations have been described
(6–8). Characteristically, the lesion appears histo-
logically as a ‘cannonball’ distribution of rounded
nodules or tufts of capillary-sized vessels in the
dermis with lymphatic vessels present at the
periphery (1, 9). The natural history of the lesion
is slow progressive growth after which it tends to
remain stable in size; in some cases, regression has
been reported (10, 11).
Tufted angioma should be distinguished from
kaposiform hemangioendothelioma (KHE),
angiosarcoma, Dabska’s malignant endovascular
papillary angioendothelioma, and Kaposi’s sar-
coma in adulthood. Multiple tufted angioma and
KHE may all be associated with the Kasabach–
Merritt syndrome (KMS), characterized by
severe thrombocytopenia and consumption of
coagulation factors (12, 13). Because the lesions
are stable and can regress spontaneously, no
treatment is recommended. However, surgical
excision or interferon alpha treatment may be
required to reduced the mass (14, 15).
Most vascular malformations occur sporadic-
ally but may also be inherited. An autosomal
dominant inheritance pattern has been described
in hereditary hemorrhagic telangiectasia (HHT),
venous malformation (VM), glomangioma and
juvenile hemangioma. Mutations in specific
genes or locus susceptibility have been identified
for these pathologies (reviewed by 16).
There has been a single report of an individual
with tufted angioma and a strong family history
of similar lesions, suggesting that a monogenic,
autosomal dominant predispositionmight exist (17).
We describe here a second family featuring
a young boy with a single tufted angioma and
four relatives also with unique lesions, in five
generations, which further suggests the existence
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of a genetic predisposition to these vascular
lesions.
Subjects and methods
Subjects
A 2-year-old male infant (V-3, no. 14898) pre-
sented with a red exophytic lesion of the upper
left back, which was not present at birth. The
family, of German origin, had a positive history
with at least four further individuals having pre-
sented single angiomatous lesions (Fig. 1), for
which no histology was available or possible.
Five immediate relatives of the index patient
were examined, and no angioma or related lesions
were detected.
Fig. 1. Family tree. Symbols are as indicated in the upper right. The results of the microsatellite analyzes are shown beneath
analyzed individuals; the tested loci are ordered as shown for the proband.
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Three women of the family also had breast
cancer, which we regard as being in all probabil-
ity independent of the predisposition to angioma.
Histology and immunohistochemistry
The lesion was surgically removed, fixed in 10%
formalin and embedded in paraffin. Antibodies
used for immunohistochemistry were as follows:
mouse monoclonal anti-human CD31 [1:100;
Clone JC/70A, Dako (Dako, Zug, Switzerland)];
mousemonoclonalanti-alphasmoothmuscleactin
[1:200(18)]; rabbitpolyclonalanti-humanLYVE-1
[1:400 (19)], kindly provided by Dr DG Jackson,
MRC Human Immunology Unit, Institute of
Molecular Medicine, John Radcliffe Hospital,
Oxford, UK; rabbit polyclonal anti-human von
Willebrand Factor (1:100, catalogue number
A0082, Dako). All antibodies were applied after
antigen retrieval (microwave) and were detected
using peroxidase-diamino-benzidine tetrahydro-
chloride (DAB). For LYVE-1 immunostaining,
antigen–antibody complexes were revealed by
means of an anti-rabbit/HRP Envision system
(Dako). Negative staining controls included omis-
sion of the primary antibody or use of an isotype-
matched irrelevant antibody (data not shown).
Genetic testing
Genomic DNA was prepared from venous blood
or buccal cells by standard techniques, after
obtaining informed consent from family mem-
bers. Genetic exclusion analysis was attempted
for five candidate loci, using linked polymorphic
microsatellite markers. Markers were selected
from the genome sequence (UCSC Genome
Browser, http://genome.cse.ucsc.edu/) (Table 1),
for their physical proximity to the candidate loci
(maximum distance accepted: 1.5Mb, equivalent
on average to 1.5% recombination). PCRs were
performed by standard techniques, with one
primer labeled with g[32P]ATP and T4 kinase. Pro-
ducts were analyzed on 40-cm 8% acrylamide/6M
urea gels. Alleles were numbered from the largest
to the smallest.
Results and discussion
Clinical examination of the index patient revealed
a 0.5-cm indurated lesion, with normal adjacent
skin (Fig. 2a). The lesion was not present at birth
but first appeared at around 18months. It grew
slowly and constantly with no growth spurts. No
regressions or involutions occurred. However,
there was frequent bleeding related to physical
trauma (it got caught on clothing or got knocked
as he played). This necessitated a permanent dress-
ing, and was the main reason for surgical exci-
sion. The clinical diagnosis was angioma or
pyogenic granuloma. Histological examination
revealed an exophytic lesion with normal adja-
cent skin. At low magnification, an edematous
dermis was noted, and the lesion presented a
characteristic ‘cannonball’ distribution of closely
packed capillary vessels which occasionally
coalesced to form larger bundles (Fig. 2b,d).
Immunohistochemical analysis revealed CD31
and vonWillebrand factor (vWF) positive endothe-
lial cells (Fig. 2c,e). Furthermore, endothelial cells
were cuffed by a-smooth muscle actin (a-SMA)
staining cells corresponding to pericytes or
smooth muscle cells (Fig. 3c) (20, 21). Dilated
vessels were present at the periphery below the
epidermis, some of which did not contain blood
(Figs 2b and 3a). The latter were vWF- and
a-SMA-negative (Fig. 3c,d). The lymphatic nature
of these vessels was confirmed by immunostain-
ing with an antibody to LYVE-1 (19), which in
the skin is specifically expressed by normal lymph-
atic and not blood vascular endothelium
(Fig. 3b). No LYVE-1 positive cells were found
in the tufts (Fig. 2f). Mitoses were rare, and no
ulceration, inflammatory infiltration or increase
in mast cell density were observed, excluding the
diagnosis of pyogenic granuloma and infantile
hemangioma. No recurrence was noted after
2 years of follow-up. Only anamnestic informa-
tion was available for the affected relatives – no
clinical or histological information could be
obtained.
The pedigree, which reveals five affected individ-
uals in five generations, does not permit formal
conclusion about the mode of heredity but is
suggestive of and is compatible with a mono-
genic, autosomal dominant trait with reduced
penetrance. According to this model, there
would be two unaffected obligatory carriers
(II-2 and IV-6) and so a maximal penetrance of
70% (5/7). This reduced penetrance might be
explained by a two-hit mutational model, whereby
loss-of-function germline and somatic mutations
are required for angioma formation [as has been
recently suggested for cerebral cavernous malfor-
mations (22)], or it may be due to unidentified
environmental or epigenetic factors. The familial
clustering could equally be explained by di- (or
poly)genic inheritance, where coincidence of two
or more ‘abnormal’ alleles is required for disease
expression,ashasbeenobservedinotherconditions
on very rare occasions (23, 24), or to coincidence,
which we consider highly unlikely because of the
rarity of the phenotype.
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Although the family size does not permit thor-
ough linkage analysis, a preliminary investigation
was performed in an attempt to exclude associ-
ation between the predisposition and certain
candidate genes. The genes selected were KDR
(kinase insert domain receptor), the principal
receptor for the angiogenic cytokine VEGF-A,
which has recently been implicated in sporadic
(a)
(b)
(c)
(d)
(e)
(f)
Fig. 2. Macroscopic and microscopic aspects of the lesion. (a) Raised vascular lesion on the back. (b) Larger irregularly sized
vascular tufts and tracts in the dermis. Haematoxylin and eosin (H & E) stain. (c) Immunohistochemistry for CD31 of the
region shown in (b). (d) ‘Cannonball’ distribution of rounded nodules or tufts of capillary-sized vessels. H & E staining. (e)
Immunohistochemistry for von Willebrand factor of the region shown in (d). (f) Immunohistochemistry for LYVE-1 shows no
lymphatic component within the tufted angioma. In (b) and (c), magnification ¼ 50. In (d), (e) and (f), magnification ¼ 100.
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common juvenile hemangioma (25), and TEK
(TEK tyrosine kinase, endothelial, formerly
TIE2), ACVRL1 (activin receptor-like kinase 1,
formerly ALK1), ENG (endoglin), FLT4 (fms-like
tyrosine kinase 4), which have all been implicated
in hereditary vascular or lymphatic malformations
(reviewed by 26). The results are depicted in Fig. 1.
KDR, ENG and FLT4 are all compatible with
linkage, with haplotypes being shared between
the three affected individuals and the one obligate
carrier available for testing. The assumption of
linkage to FLT4 would imply that individual IV-7
was a further unaffected carrier. These results are
also compatible with the polygenic model men-
tioned above. TEK can be essentially excluded, as
no alleles are shared between affected individuals
III-2 and V-3, as can ACVRL1, for which it would
be necessary to presume the occurrence of two
meiotic recombinations to explain linkage.
In conclusion, we report the second familial
occurrence of tufted angioma. As in the previ-
ously reported family (17), the mode of inher-
itance is compatible with a monogenic
autosomal dominant trait with reduced pene-
trance, although a more complex polygenic
model is also possible. We also present clear evi-
dence for the presence of dilated lymphatic vessels
at the periphery of the lesion in the index case.
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DISCUSSION 
 
L'importance de la famille des VEGF dans l'établissement du système vasculaire 
chez l'embryon, ainsi que lors de l'angiogenèse physiologique et pathologique chez 
l'adulte, m'a amené à étudier le rôle des récepteurs à VEGF exprimés par les cellules 
endothéliales. J'ai employé un modèle de tubulogenèse in vitro qui récapitule la 
phase d'activation de l'angiogenèse (Montesano and Orci, 1985). En présence de 
facteurs angiogéniques, les cellules endothéliales vont proliférer, dégrader la matrice 
extra-cellulaire et migrer dans celle-ci en formant des bourgeons cylindriques 
creusés ultérieurement d'une lumière centrale. 
 
 
L'UTILISATION D'INHIBITEUR DES VEGFR DANS L'ANGIOGENÈSE 
IN VITRO ET IN VIVO INDUITE PAR FGF-2 
 
J'ai choisi plusieurs approches afin d'élucider la fonction des VEGFR dans 
l'angiogenèse induite par FGF-2. Premièrement, j'ai utilisé des inhibiteurs 
synthétiques de la phosphorylation des récepteurs de type tyrosine kinase, des 
anticorps monoclonaux neutralisant sélectivement VEGFR-1, -2 ou -3, ainsi que des 
ligands spécifiques pour chacun de ces trois récepteurs.  
 
Les trois inhibiteurs de la phosphorylation que j'ai utilisés sont spécifiques pour la 
famille des VEGFR avec une plus grande efficacité contre VEGFR-2 que contre 
VEGFR-1 et VEGFR-3. J'ai testé l'activité de ces inhibiteurs dans un modèle 
d'angiogenèse in vivo et un modèle d'angiogenèse in vitro induite par des facteurs de 
croissance endothéliaux, comme VEGF-A et FGF-2. L'angiogenèse in vivo induite 
par VEGF-A est pratiquement complètement bloquée par ces trois inhibiteurs et ceci 
de façon dose-dépendante. Il ressort que le AAD 777 est efficace à des 
concentrations inférieurs par rapport aux deux autres inhibiteurs, bien que celui-ci a 
un IC50 supérieur aux autres inhibiteurs et ceci dans les tests de phosphorylation in 
vitro et dans l'inhibition de la prolifération des HUVEC induit par VEGF-A. Cette 
différence entre l'effet in vitro et in vivo pourrai être due à l'inhibition d'autres kinases 
non étudiées in vitro.  
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Avec grande surprise, j'ai observé que l'angiogenèse in vivo induite par FGF-2 était 
également partiellement inhibée de façon dose-dépendante par ces trois 
composants. Cette inhibition est intéressante car ces substances sont quasiment 
inactives contre les récepteurs à FGF dans les tests de phosphorylation in vitro et 
dans la prolifération des HUVEC induite par FGF-2. Le AAC 789 a déjà une activité 
inhibitrice pratiquement maximale à une concentration de 12.5 mg/kg/jour sur 
l'inhibition de l'angiogenèse in vivo induite par FGF-2. Le PTK 787 montre une 
efficacité quasi identique sur l'inhibition de l'angiogenèse induite par VEGF-A et FGF-
2.  
 
Dans le modèle d'angiogenèse in vitro, j'ai retrouvé cette inhibition de l'angiogenèse 
induite par VEGF-A et FGF-2 avec les inhibiteurs de la phosphorylation de VEGFR-2. 
Contrairement à l'angiogenèse in vivo, le PTK 787 montre une meilleure efficacité sur 
l'inhibition de FGF-2 que VEGF-A et ceci uniquement avec les cellules endothéliales 
de type macrovasculaire, les BAE. Par contre, les trois inhibiteurs ont la même 
efficacité sur l'inhibition de l'angiogenèse in vitro induite par VEGF-A avec les cellules 
endothéliales provenant de l'arbre microvasculaire, les BME. Cette différence est une 
observation et je n'ai pas d'explication rationnelle. 
 
Cette inhibition de l'angiogenèse induite par FGF-2 m'a amené à essayer d'élucider 
un possible mécanisme d'action dans un modèle in vitro de culture cellulaire. 
Premièrement, j'ai exclu une transphosphorylation de VEGFR-2 par la stimulation 
avec FGF-2 des cellules endothéliales bovines pendant 8 minutes et 8 heures. 
Deuxièmement, j'ai regardé si l'inhibition des VEGFR pourrait interrompre une boucle 
endogène et autocrine des membres de la famille des VEGF induite par FGF-2. Pour 
cela, j'ai analysé quels membres de la famille des VEGF sont exprimés dans nos 
cellules endothéliales bovines et si ceux-ci sont augmentés suite à la stimulation par 
FGF-2. Les deux types cellulaires, les BME et les BAE, expriment VEGF-A164, VEGF-
A120, VEGF-B et VEGF-C mais pas VEGF-D. La stimulation par FGF-2 n'augmente 
pas de manière significative l'expression de ces différentes cytokines dans nos 
cellules endothéliales.  
 
Sachant que FGF-2 induit une augmentation de l'expression de VEGFR-2 dans les 
cellules endothéliales bovines (Pepper and Mandriota, 1998), j'ai recherché si les 
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ligands endogènes de ce récepteur, VEGF-A et VEGF-C, sont impliqués dans une 
boucle autocrine conduisant à l'activation de VEGFR-2 lors de l'angiogenèse induite 
par FGF-2. Pour cela, j'ai employé des récepteurs solubles, VEGFR-1-Ig et VEGFR-
3-Ig, captant VEGF-A et VEGF-C respectivement, ainsi que deux anticorps anti-
VEGFR-2 neutralisant la liaison et l'activation de VEGFR-2 par VEGF-A et VEGF-C 
et un anticorps anti-VEGF-A. J'ai observé avec ces anticorps ou ces récepteurs 
solubles une inhibition de 50% de l'angiogenèse in vitro induite par FGF-2. Ces 
résultats démontrent l'existence d'une boucle autocrine de VEGF-A et VEGF-C 
activant VEGFR-2 dans les cellules endothéliales bovines. Par contre, l'efficacité en 
terme d'inhibition de l'angiogenèse in vitro est plus importante avec les inhibiteurs de 
la phosphorylation qu'avec l'utilisation des anticorps. Ceci pourrait refléter une 
activation de VEGFR-2, indépendant du ligand, par le fait de l'augmentation de son 
expression par FGF-2.  
 
Pour approfondir nos connaissances sur les mécanismes cellulaires affectés par 
l'inhibition de VEGFR-2, j'ai ensuite analysé le rôle de ce récepteur dans la 
prolifération, la migration et l'induction des activateurs du plasminogène, suite au 
traitement des cellules endothéliales bovines par FGF-2. J'ai observé qu'uniquement 
la prolifération cellulaire est diminuée de manière significative par les inhibiteurs de la 
phosphorylation de VEGFR-2. Ces résultats contredisent ceux obtenus avec les 
HUVEC dans lesquelles ces inhibiteurs n'ont pas d'effet sur la prolifération induite par 
FGF-2. Il serait judicieux de déterminer si ceci reflète une différence entre espèce, 
car les HUVEC sont des cellules endothéliales humaines à moins qu'il s'agisse d'une 
différence dans la méthode d'analyse de la prolifération cellulaire entre ces 
expériences. 
 
Il ressort de cette première partie que l'inhibition de VEGFR-2 est efficace pour 
bloquer l'angiogenèse induite par VEGF-A et également celle induite par FGF-2 in 
vitro et in vivo. De plus, l'efficacité des inhibiteurs de la phosphorylation des VEGFR 
est meilleur que celle des anticorps neutralisant VEGFR-2.  
 
L'utilisation des inhibiteurs de VEGFR-2 dans une thérapeutique, en combinaison 
avec d'autres méthodes, semble avoir un avenir fort prometteur dans le traitement 
des tumeurs (Willett et al., 2004). Premièrement, l'angiogenèse tumorale n'est pas 
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induite uniquement par une cytokine angiogénique mais par l'effet additif voir 
synergique de différentes cytokines (Bergers and Benjamin, 2003). Deuxièmement, 
l'inhibition de VEGFR-2 permet de bloquer d'une part l'action de VEGF-A mais 
également, de façon moindre, celle de FGF-2 et VEGF-C (voir ci-dessous). 
 
 
LE RÔLE DES VEGFR DANS L'ANGIOGENÈSE IN VITRO ET DANS 
L'EXPRESSION DES GÈNES 
 
Dans ce modèle d'angiogenèse in vitro, il a été préalablement montré que la 
tubulogenèse des cellules endothéliales bovines pouvait être induite par divers 
membres de la famille des VEGF (Pepper et al., 1992; Pepper et al., 1998). Le profil 
d'expression des VEGFR exprimés par ces cellules est connu, VEGFR-1 et VEGFR-
2 sont exprimés par les BME et les BAE, tandis que VEGFR-3 est présent 
uniquement dans les BAE (Pepper and Mandriota, 1998; Pepper et al., 1998). Afin 
de distinguer le ou lesquels de ces récepteurs sont nécessaires au processus 
d'angiogenèse in vitro et à l'induction du système des activateurs du plasminogène 
par la famille des VEGF, j'ai choisi de stimuler chaque VEGFR individuellement 
grâce à des ligands spécifiques, obtenus par mutagenèse.  
 
Dans le modèle d'angiogenèse in vitro les ligands activant VEGFR-1, comme PlGF, 
VEGF-B167/186 et VFM17, n'induisent pas l'invasion des cellules endothéliales. Par 
contre, les ligands de VEGFR-2, le VEGF-A et le VFM23A, induisent une 
angiogenèse in vitro de même intensité. Le synergisme entre FGF-2 et VEGF-A n'est 
pas induit par les ligands de VEGFR-1, mais uniquement part ceux de VEGFR-2, 
VEGF-A, VFM23A, VEGF-C, VEGF-C152. De plus, un anticorps neutralisant VEGFR-
1 n'affecte pas l'invasion induite par VEGF-A dans les deux lignées de cellules 
endothéliales (résultats non publiés). Ces résultats suggèrent que VEGFR-1 n'est 
pas impliqué dans la tubulogenèse induite par VEGF-A dans ce modèle 
d'angiogenèse in vitro. Par contre, il a récemment été publié que VEGFR-1 pourrait 
intervenir dans l'angiogenèse induite par FGF-2 (Kanda et al., 2004). 
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L'utilisation de ligands spécifiques pour VEGFR-2 et/ou VEGFR-3, tel que VEGF-A, 
VFM23A, VEGF-C et VEGF-C152, induisent une réponse similaire en terme 
d'angiogenèse in vitro. Ces résultats sont accord avec les données récentes de la 
littérature concernant le rôle primordial de VEGFR-2 dans la réponse biologique des 
cellules endothéliales suite à l'activation par VEGF-A. 
 
Par contre, les cytokines mutantes, VEGF-C156 et VEGF-C152, liant spécifiquement 
VEGFR-3 humain induisent une réponse angiogénique différente. VEGF-C152 est 
aussi actif que VEGF-C, tandis que VEGF-C156 est inactif. Ce résultat m'a amené à 
rechercher si le profil de liaison de ces deux mutants à VEGFR-3 est conservé dans 
les cellules endothéliales d'origine bovine. VEGF-C156 n'induit pas la phosphorylation 
de VEGFR-3 bovin, ni de VEGFR-2, tandis que VEGF-C152 active VEGFR-2 bovin en 
plus de VEGFR-3 comme le VEGF-C. Ces résultats indiquent d'une part qu'il existe 
une interaction ligand-récepteur qui est spécifique selon les espèces et renforce 
l'importance de VEGFR-2 dans nos cellules endothéliales. 
 
L'augmentation transitoire de l'ARN messager des activateurs du plasminogène (t-
PA, u-PA), de u-PAR et de PAI-1, est uniquement induite par les ligands de VEGFR-
2 et/ou VEGFR-3, tel que VEGF-A, VFM23A et VEGF-C. Dans les BAE, qui 
expriment VEGFR-2 et -3, t-PA est plus fortement induit par VEGF-C que par VEGF-
A. Par contre, les BME, qui n'expriment pas VEGRFR-3, t-PA est induit plus 
fortement par VEGF-A que par VFM23A et VEGF-C. Ces résultats montrent d'une 
part que VEGFR-1 n'intervient pas dans l'induction des activateurs du plasminogène, 
mais d'autre part ils indiquent aussi qu'il existe une différence entre les BAE et les 
BME dans la régulation de t-PA. Celle-ci pourrait résider dans une différence 
d'expression des VEGFR ou de co-récepteur, comme les neuropilins. Afin de 
démonter que VEGFR-1 ne joue aucun rôle dans l'invasion et la régulation 
d'expression de gènes dans les BME et les BAE, il faudrait s'assurer que celui-ci est 
bien phosphorylé suite à l'ajout de VEGF-B167/186 et PlGF. 
 
Afin de clairement distinguer l'activité de VEGF-C par VEGFR-2 et VEGFR-3, j'ai 
utilisé des anticorps monoclonaux neutralisant VEGFR-2 et VEGFR-3 dans le 
modèle d'angiogenèse in vitro. L'angiogenèse induite par VEGF-A est totalement 
inhibée par les anticorps neutralisant VEGFR-2, confirmant les données obtenues à 
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l'aide des inhibiteurs de la phosphorylation. L'anticorps neutralisant VEGFR-3 
n'affecte pas l'invasion induite par VEGF-A (Persaud et al., 2004). Ces résultats 
démontrent que, dans les cellules endothéliales bovines, l'activité de VEGF-A se fait 
uniquement par l'intermédiaire de sa liaison à VEGFR-2. La tubulogenèse induite par 
VEGF-C et VEGF-C152 n'est que partiellement inhibée par les anticorps neutralisant 
VEGFR-2 ou VEGFR-3. L'addition conjointe des anticorps anti-VEGFR-2 et anti-
VEGFR-3 permet d'inhiber totalement l'angiogenèse in vitro induite par VEGF-C 
(Persaud et al., 2004). Ces résultats démontrent que VEGF-C induit l'invasion des 
cellules endothéliales bovines par l'activation de VEGFR-2 ainsi que de VEGFR-3. 
De plus, l'activation simultanée des deux récepteurs permet de potentialiser la 
réponse induite par VEGF-C. Récemment, il a été reporté la formation 
d'hétérodimère fonctionnel composé de VEGFR-2 et VEGFR-3, suite à la stimulation 
par VEGF-C (Dixelius et al., 2003). Cette potentialisation pourrait s'expliquer par la 
formation d'hétérodimère VEGFR-2/-3, mais également par une modification des 
voies de signalisation intra-cellulaire.  
 
L'utilisation d'un inhibiteur de la phosphorylation des trois VEGFR, le SU5416, bloque 
totalement l'angiogenèse in vitro induite par VEGF-A et VEGF-C. En ce qui concerne 
les BAE, j'ai observé que VEGF-A induit une plus forte phosphorylation de VEGFR-2 
que VEGF-C. Par contre, l'activation de la voie de signalisation des MAPkinase, 
ERK1 et ERK2, qui participe à la prolifération cellulaire, est moins fortement activée 
par VEGF-A que par VEGF-C. Ces résultats soutiennent l'hypothèse qu'il existe une 
différence d'activation de voies signalétiques suite à la phosphorylation de VEGFR-2 
par VEGF-A et VEGF-C. 
 
En conclusion de cette étude, j'ai démontré l'importance de l'activation de VEGFR-2 
dans l'angiogenèse induite par VEGF-A et VEGF-C dans les BAE. De plus, l'activité 
complète de VEGF-C nécessite l'activation simultanée de VEGFR-3 et de VEGFR-2. 
Par contre, VEGFR-2 qui est activé par VEGF-A et VEGF-C dans les BME n'est pas 
suffisant pour permettre l'angiogenèse in vitro induite par VEGF-C. Ceci suggère de 
nouveau un rôle pour les neuropilins, des co-récepteurs aux VEGF, dans la capacité 
angiogénique des cellules endothéliales.  
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 MODIFICATION DE L'ANGIOGENÈSE IN VITRO PAR LES CELLULES 
MÉSENCHYMATEUSES 
 
L'angiogenèse in vivo fait intervenir d'une part les cellules endothéliales, d'autre part 
les cellules péri-vasculaires comprenant les péricytes, les cellules musculaires lisses, 
ainsi que les cellules mésenchymateuses, les précurseurs de cellules péri-
vasculaires.  
 
J'ai cherché à savoir si dans des modèles tridimensionnels d'angiogenèse in vitro, la 
présence de cellules mésenchymateuses pluripotentes (cellules 10T1/2) pouvant se 
différencier en cellules musculaires lisses, pouvait moduler l'invasion induite par 
VEGF-A ou FGF-2. J'ai observé que les cellules mésenchymateuses n'induisent pas 
d'invasion spontanée des cellules endothéliales en co-culture. Par contre, les 10T1/2 
inhibent l'angiogenèse induite par FGF-2 en co-culture lorsqu'un contact est possible 
entre les deux types cellulaires. L'interposition d'une couche de collagène entre les 
deux types cellulaires, empêchant ainsi un contact direct, restaure l'angiogenèse in 
vitro induite par FGF-2. Concernant l'invasion induite par VEGF-A, la présence de 
cellules mésenchymateuses potentialise celle-ci indépendamment d'un contact entre 
les deux types cellulaires. De plus, j'ai identifié un mécanisme de synergisme entre 
les cellules mésenchymateuses et VEGF-A dans l'augmentation de l'angiogenèse in 
vitro. Ces résultats indiquent que les cellules mésenchymateuses ont un potentiel de 
moduler l'angiogenèse induite par différents facteurs de croissance. Cette modulation 
est activatrice pour VEGF-A et inhibitrice pour FGF-2. De plus, le contact entre les 
deux types cellulaires est nécessaire à l'inhibition de l'invasion induite par FGF-2, 
mais ne participe pas à la modulation de l'angiogenèse in vitro induite par VEGF-A. Il 
ressort que deux mécanismes d'actions différents existent. L'inhibition de FGF-2 fait 
certainement intervenir une interaction entre des protéines membranaires, comme 
par exemple les Sprouty qui régulent négativement les récepteurs à FGF (Cabrita 
and Christofori, 2003). 
 
Je me suis particulièrement focalisé sur l'augmentation de l'angiogenèse in vitro par 
VEGF-A. Premièrement, j'ai recherché si ces cellules mésenchymateuses 
exprimaient VEGF-A et des VEGFR, puis si ceux-ci intervenaient dans la 
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potentialisation de l'angiogenèse induite par VEGF-A. Par RT-PCR, j'ai trouvé que 
les cellules mésenchymateuses expriment VEGF-A164, VEGF-A120 et VEGFR-1. Pour 
premièrement exclure une participation de VEGF-A sécrété par les cellules 
mésenchymateuses, j'ai utilisé un anticorps anti-VEGF-A murin dans le modèle de 
co-culture. L'inhibition de VEGF-A murin diminue légèrement l'invasion en co-culture 
mais celle-ci reste bien supérieur celle induite dans les cellules endothéliales seuls. 
Ce résultat indique que VEGF-A provenant des cellules mésenchymateuses participe 
de façon accessoire à l'angiogenèse in vitro en co-culture. Grâce aux mutants de 
VEGF-A qui lient spécifiquement VEGFR-1 ou VEGFR-2, ainsi qu'à un inhibiteur de 
la phosphorylation de VEGFR-2, j'ai pu démontrer que l'augmentation de 
l'angiogenèse in vitro en co-culture se fait par l'intermédiaire de l'activation de 
VEGFR-2, qui est exprimé uniquement par les cellules endothéliales.  
 
Ces résultats m'ont amené à émettre l'hypothèse suivante: suite à la stimulation de 
VEGFR-2 par VEGF-A, les cellules endothéliales sécrètent un facteur diffusible qui 
interagit avec les cellules mésenchymateuses et qui vont à leur tour libérer un facteur 
potentialisant l'invasion des cellules endothéliales.  
 
J'ai tenté de reproduire cette augmentation de l'angiogenèse en co-culture à l'aide de 
milieux conditionnés de co-culture et de "trans-well" afin de pouvoir, par la suite, 
isoler le facteur responsable. Des résultats malheureusement négatifs dans les deux 
tests suggèrent que le facteur putatif soit relativement instable ou qu'il reste fixé à la 
matrice extracellulaire, réduisant ainsi sa capacité de diffusion. Le rôle de la matrice 
extra-cellulaire dans la capacité de diffusion de ce facteur est aisément vérifiable en 
remplaçant le collagène de type I par une matrice de fibrine permettant une meilleur 
diffusion. 
 
Il a été récemment publié que la famille des Angiopoïetin module l'angiogenèse in 
vitro et in vivo induite par VEGF-A. Dans notre modèle d'angiogenèse in vitro, j'ai 
observé qu'Ang-1 et non Ang-2 potentialise l'invasion induite par VEGF-A. De plus 
cette potentialisation est spécifiquement inhibée par le récepteur aux Angiopoïétin 
sous une forme soluble (Tie2-Fc) et ceci sans affecter l'angiogenèse in vitro induite 
par VEGF-A. Par RT-PCR, j'ai trouvé que les cellules 10T1/2 expriment l'ARN 
messager d'Ang-1, mais pas Ang-2, suggérant une implication de cette cytokine dans 
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l'augmentation de l'invasion induite par VEGF-A en co-culture. Par contre, l'ajout de 
Tie2-Fc dans le milieu de culture ou dans le gel de collagène, n'affecte pas l'invasion 
en co-culture. Ces résultats suggèrent fortement qu'Ang-1 n'est pas le facteur 
responsable de cette potentialisation de l'invasion en co-culture. 
 
Au moyen d'anticorps neutralisants ou d'inhibiteurs de récepteurs contre les 
principales molécules connues à ce jour qui interviennent dans la régulation de 
l'angiogenèse ou qui modulent l'interaction entre les cellules endothéliales et les 
cellules péri-vasculaires, j'ai pu exclure que FGF-2, TGF-β1, PDGF-BB, PDGF-AA, 
NO, PlGF, PD-ECGF, IL-8, HGF, EGF et G-CSF sont responsable de l'angiogenèse 
en co-culture. 
 
J'ai utilisé un second modèle de co-culture dans lequel les cellules endothéliales sont 
mis en "sandwich" entre deux couches de collagène récapitulant ainsi la phase de 
résolution de l'angiogenèse. Dans ce modèle, j'ai observé qu'en augmentant le 
nombre de cellules mésenchymateuses incorporées dans les gels de collagène des 
co-culture que la formation de structures ressemblant à des capillaires par les 
cellules endothéliales diminuent d'une manière proportionnelle. L'addition de FGF-2 
au cellules endothéliales seules et au co-culture en "sandwich" n'a aucun effet sur la 
réorganisation des cellules endothéliales dans ce modèle. Par contre, VEGF-A 
augmente cette réorganisation et de plus celle-ci se trouve également potentialisée 
par la présence de cellules mésenchymateuses. 
 
Il est intéressant de noté que FGF-2 ne module pas la réorganisation en capillaire 
dans le second modèle en "sandwich" bien qu'il soit un facteur angiogénique dans le 
modèle de mono-couche. Donc, il semble que FGF-2 participe aux étapes d'initiation 
de l'angiogenèse et non à l'étape de résolution.  
 
En conclusion de cette étude, j'ai démontré, dans deux modèles d'angiogenèse in 
vitro, que la présence de cellules mésenchymateuses potentialisent spécifiquement 
l'angiogenèse induite par VEGF-A. J'ai pu exclure l'implication de plusieurs cytokines 
impliquées dans l'interaction entre cellules endothéliales et cellules périvasculaires, 
mais je n'ai pas réussi à définir le ou les facteur(s) impliqué(s). Ces résultats 
soulignent l'importance de la coopération qui s'effectue entre les différents types 
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cellulaires intervenant dans l'angiogenèse. Une meilleure compréhension des 
mécanismes qui gouvernent cette interaction devrait conduire à l'identification de 
nouveaux facteurs impliqués dans la régulation de l'angiogenèse in vivo. 
 
En perspective de cette étude, on peut envisager de produire une banque d'ADN 
complémentaire des cellules 10T1/2 puis de transfecter des cellules ne modulant pas 
l'activité angiogénique de FGF-2 et VEGF-A, afin d'identifier les facteurs 
responsables de l'inhibition de FGF-2 et ceux potentialisant l'activité de VEGF-A. 
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ANGIOME EN TOUFFE: PRÉDISPOSITION FAMILIALE 
 
Les malformations vasculaires sont des lésions au sein desquelles on trouve des 
anomalies affectant aussi bien les vaisseaux sanguins que lymphatiques. La majorité 
de ces malformations apparaissent sporadiquement, mais elles peuvent aussi être 
héritées (Brouillard and Vikkula, 2003; Tille and Pepper, 2004).  
 
J'ai étudié une famille atteinte d'une malformation vasculaire appelée angiome en 
touffe. Histologiquement, on observe des amas de vaisseaux de petites tailles, aussi 
appelé touffe, qui sont séparés les uns des autres par du tissu conjonctif. Des 
vaisseaux de plus grandes tailles, ne contenant pas de globules rouges, sont présent 
à la périphérie de cette lésion. Pour caractériser le type de vaisseaux présents à la 
périphérie et dans les touffes de cet angiome, j'ai utilisé, un anticorps anti-CD31, un 
marqueur pan-endothélial, un anticorps anti-LYVE-1, un marqueur de cellules 
lymphatiques, un anticorps anti-facteur VIII et un anticorps anti-alpha-actine muscle 
lisse, un marqueur de cellules périvasculaires. Les vaisseaux en périphérie sont 
positifs pour le CD31, le LYVE-1 et sont négatifs pour l'alpha-actine du muscle lisse. 
Dans les touffes, les vaisseaux sont positifs pour le CD31 et l'alpha-actine du muscle 
lisse, mais sont négatifs pour le LYVE-1. Donc, il ressort que deux types de 
vaisseaux sont présents dans l'angiome en touffe. Des vaisseaux lymphatiques sont 
distribués en périphérie tandis que des vaisseaux sanguins sont présents 
uniquement dans les touffes.  
 
Est-ce que la distribution en périphérie de vaisseaux lymphatiques ectatiques résulte 
d'une adaptation hyperplasique du réseau pré-existant ou d'une lymphagiogenèse? 
Une étude sur l'index de prolifération de cellules endothéliales de types sanguines ou 
lymphatiques, dans plusieurs lésions d'angiome en touffe pourrait permettre 
d'approfondir nos connaissances dans sa pathogenèse et la possible mixité 
vasculaire de cette lésion. 
 
Dans la famille étudiée, cinq membres sont atteints sur cinq générations, ce qui est 
compatible avec un mode de transmission autosomal dominant avec une pénétrance 
réduite, qui est estimée à 70%. Le nombre de patients n'étant pas assez important 
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pour permettre une analyse de lien génétique approfondie, nous avons choisi 
d'exclure une association entre la transmission de certains gènes impliqués dans le 
développement de malformations vasculaires, et une prédisposition à l'angiome en 
touffe. Les gènes étudiés sont VEGFR-2, VEGFR-3, TEK (Tie2), ENG et ACVRL1. 
Par analyse de marqueurs microsatellites polymorphes pour chacun de ces loci, 
nous avons pu exclure un lien entre la transmission des gènes codant pour TEK et 
ACVLR1 et le développement d'angiome en touffe. Par contre, les haplotypes pour 
VEGFR-2, VEGFR-3 et ENG sont compatibles avec une liaison, mais ces résultats 
ne permettent pas de les incriminer dans une prédisposition ou dans la pathogenèse 
de cette malformation.  
 
Il ressort de l'analyse de malformations vasculaires héréditaires qu'une ou de 
multiples mutations somatiques serait nécessaire à leurs développements, comme 
par exemple dans les hémangiomes, les glomangiomes et les carvernomes 
cérébraux (Tille and Pepper, 2004). Des mutations somatiques de VEGFR-2 et 
VEGFR-3 ont été trouvées dans les hémangiomes (Walter et al., 2002). Il serait fort 
intéressant de rechercher des mutations somatiques de ces gènes dans l'angiome 
en touffe.  
 
A ce jour, la famille que nous avons étudiée est la seconde décrite dans la littérature. 
L'identification d'autres familles permettrait d'approfondir l'étude génétique et 
d’identifier le(s) gène(s) en cause dans cette maladie ou dans des gènes 
prédisposant à des malformations vasculaires. 
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PERSPECTIVES 
 
De ces différentes études, il ressort plusieurs points essentiels. Premièrement, 
VEGF-C induit l'angiogenèse in vitro uniquement dans les BAE qui expriment 
VEGFR-3. Par contre, j'ai montré que VEGF-C induit la phosphorylation de VEGFR-2 
dans les deux lignées cellulaires, les BME et les BAE. De plus, t-PA est augmenté 
par VEGF-C dans les BAE et VEGF-A dans les BME. Ceci montre qu'il existe une 
hétérogénéité entre les différents types de cellules endothéliales d'une même 
espèce. Il semble donc que l'origine des cellules endothéliales, micro ou 
macrovasculaires ainsi que vasculaires ou lymphatiques, doit être intégré de façon 
beaucoup plus attentive dans la réponse à différents stimuli. De plus, une analyse 
protéomique de ces différents types de cellules endothéliales va certainement révéler 
des fonctions cellulaires inattendues. 
 
Un autre axe de recherche concerne les malformations vasculaires. Bien que celles-
ci soit assez rares, la recherche de familles atteintes ainsi qu'un grand nombre de 
cas sporadiques permettrait d'une part d'essayer trouver de des gènes responsables 
ou prédisposant à ces maladies. L'hypothèse de la survenue de mutations 
somatiques pourrait aussi être analysée de manière plus systématique en les 
recherchant au sein des lésions dans des gènes que l'on sait être impliquer dans 
l'angiogenèse.  
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